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SUMMARY23
SUMMARYAlthough most Escherichia coli isolates are harmless commensals of the 
gastrointestinal tract, some strains have acquired specific virulence factors, like 
pathogenicity islands, insertion elements (IEs), and prophages (PPs), to become 
highly adapted pathogens. The enteropathogenic E. coli (EPEC) is an important 
category of diarrheagenic bacteria causing acute and chronic diarrhea in infants. 
The hallmark of EPEC infection is the formation of attachment and effacement 
(A/E) lesion in the intestinal mucosa surface, which is characterized by the 
intimate attachment of the bacteria to the enterocyte, microvilli effacement, and the 
formation of actin-pedestal-like structures underneath the attached bacteria. EPEC 
is endowed of a 35 kb pathogenicity island called the locus of enterocyte effacement 
(LEE) that contains all the genes necessary for the assembly of a type III secretion 
system (T3SS) injectisome.  Through these injectisome EPEC translocates multiple 
effector proteins into the host cell to subvert cellular functions in benefit of the 
infection. The prototype strain E2348/69 of EPEC O127:H6 is endowed of six LEE 
encoded effectors and 17 non-LEE encoded effectors. We have engineered a set of 
effector mutant EPEC strains using suicide vectors to delete the whole repertoire 
of effector genes of this prototype EPEC strain. Genome manipulation did not 
affect the functionality of the T3SS injectisome. The deletion strategy was based on 
suicide or termosensitive plasmid integration by homologous recombination and 
the markerless resolution of co-integrants after I-SceI digestion. We did markerless 
integration of map, espH and nleC in their original locus in EPEC2 (maintain EspZ 
and Tir), EPEC1 (maintaining only Tir) and EPEC0 (effector-less) mutant strains. 
These strains were able to translocate functional effectors from chromosomal 
expression into HeLa cells. We infected intestinal human biopsies with the effector 
mutant EPEC strains to identify the effectors necessary for the induction of the 
A/E lesion in human intestinal tissues. We found that while EPEC2 and EPEC1 
mutant strains were able to induce the actin-pedestal formation in HeLa cells in 
vitro, none of the biopsies infected with these strains had A/E lesion. These results 
demonstrated that effectors besides Tir and EspZ are essential to induce the A/E 
lesion formation in intestinal biopsies. We infected intestinal biopsies with several 
effector mutant EPEC strains and we found that effectors located outside the LEE are 
essential to induce efficient A/E lesion on human intestinal biopsies.  Additionally 
we found that non-LEE effectors are characterized by having an additive effect to 
allow the A/E lesion development in these intestinal surfaces and that Efa1/LifA 
homologous proteins seem to play a major role in this process. Our results with 
intestinal biopsies strongly suggest that non-LEE effectors are necessary for the 
efficient formation of A/E lesion in the in vivo situation.
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RESUMEN
Aunque la mayoría de los aislados de Escherichia coli son comensales del tracto 
gastrointestinal, algunas cepas han adquirido factores de virulencia específicos, 
como islas de patogenicidad, elementos integrativos (IEs), y profagos (PPs), para convertirse en patógenos altamente adaptados. La cepas de Escherichia coli enteropatógena (EPEC) son una categoría importante de bacterias productoras 
de diarrea aguda y crónica en niños de corta edad. La característica distintiva 
de la infección por EPEC es la formación de la lesión llamada de unión y borrado 
A/E (Attaching and Effacing lesion), que se caracteriza por una unión intima de la 
bacteria a los enterocitos, la destrucción de las microvellosidades, y la formación de 
estructuras en forma de pedestales debajo de las bacterias unidas. EPEC está dotada 
de una isla de patogenicidad de 35 kb llamada LEE (locus of enterocyte effacement) 
que contiene todos los genes necesarios para ensamblar los inyectisomas del 
sistema de secreción tipo III (T3SS). A través de estos inyectisomas EPEC transloca 
proteínas efectoras a la célula huésped para manipular diversas funciones celulares 
en beneficio de la infección. La cepa prototipo E2348/69 de EPEC O127:H6 tiene 
seis efectores codificados en la isla LEE y 17 efectores codificados fuera de la isla LEE, 
llamados genéricamente efectores no-LEE. Hemos construido un grupo de cepas 
mutantes en efectores de EPEC, utilizando vectores suicidadas para delecionar el 
repertorio de efectores de la cepa prototipo. La manipulación genómica no afectó 
la funcionalidad de los inyectisomas del T3SS.  La estrategia seguida se basa en el 
uso de plásmidos suicidas y termosensibles que se integran por recombinación 
homóloga, seguida de una resolución de los co-integrantes tras digestión con 
I-SceI, produciendo deleciones libres de marcadores. También hemos realizado una integración libre de marcas de los genes map, espH y nleC en su sitio original en el 
cromosoma de las cepas mutantes EPEC2 (mantiene EspZ y Tir), EPEC1 (mantiene 
Tir) y EPEC0 (sin efectores). Las cepas generadas son capaces de translocar desde 
su expresión cromosómica los efectores individuales de forma funcional a células 
HeLa. Infectamos biopsias intestinales humanas con las cepas de EPEC mutantes 
en efectores para identificar los efectores necesarios para inducir la formación de 
la lesión A/E en tejidos intestinales humanos. Identificamos que mientras las cepas 
mutantes EPEC2 y EPEC1 inducen la formación de pedestales de actina durante 
la infección in vitro de células HeLa, ninguna de las biopsias infectadas por estas 
cepas  presentó lesiones A/E.  Estos resultados demuestran que otros efectores 
además de Tir y EspZ son esenciales para inducir la formación de la lesión A/E 
en las biopsias intestinales. Infectamos biopsias intestinales con varias cepas de 
EPEC mutantes en efectores y descubrimos que los efectores localizados fuera 
de la isla LEE son esenciales para inducir eficientemente la lesión A/E en las 
biopsias intestinales humanas.  Además demostramos que los efectores no-LEE 
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se caracterizan por tener un efecto aditivo para permitir el desarrollo de la lesión 
A/E en estas superficies intestinales y que las proteínas homologas a Efa1/LifA 
parecen jugar un papel principal en este proceso. Nuestros resultados con biopsias 
intestinales apoyan un papel de los efectores no-LEE  en la formación eficiente de 
la lesión A/E en la situación in vivo. 
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1. Importance of the human-microbiota interaction
Humans appeared in the evolutionary scene of the Earth 3.5 billions years after microorganisms. Bacteria were necessary to make the Earth habitable; they put 
the first molecular oxygen in the Earth’s atmosphere, creating the ozone layer and 
the conditions that permitted the later evolution of oxygen-utilizing creatures such as humans.  Microorganisms are spread in all parts of Earth. They live in the artic 
ice, in the subsurface of the land, in the air and also in hot springs (Abigail, Salyer 
et al. 2002). Microorganisms are also present in humans, establishing a large and 
dynamic collection of microbes called microbiota, which colonizes body surfaces 
covered by epithelial cells exposed to the external environment like gastrointestinal 
tract, respiratory tract, skin and vagina (Tlaskalova-Hogenova, Stepankova et al. 2004).  Microbiota is central for maintaining a healthy environment and giving 
some metabolic benefits and acting as a barrier against pathogens (Mai 2004, Bull and Plummer 2014).  The number of bacteria present in mucosal surfaces and 
skin is similar or even exceeds the number of cells that conform the human body 
(Sender, Fuchs et al. 2016). The majority of these microbial cells representing the 
70% are localized in big conglomerates of microbes in the intestinal gut, thereby the impact of these microbes in human physiology is likely to be more pronounced 
in the intestine. In the proximal and middle small intestine the microbial density is relatively low but it increase in the distal small intestine to 108 bacteria/ml of luminal content and in the colon it increase to 1012/gram (Hooper, Midtvedt et al. 2002). The combined microbiome has been studied by metagenomic approaches 
revealing that it exceeds the complexity of the human genome (Mai 2009). By recruiting these resident microbes with metabolic capabilities the host is relieved 
of the need to evolve such functions.  Through its immense metabolic capabilities, 
the gut microbiota contributes to human physiology by transforming complex 
nutrients, like dietary fiber into simple sugars and other nutrients that can be 
absorbed and otherwise the host will lose this energy source (Hooper, Midtvedt et al. 2002). 
The main interaction between host immune system and the external environment 
is the intestinal epithelium surface, this continuous and dynamic interaction is important for the development and maturation of the host immune system 
(Bull and Plummer 2014, Landman and Quevrain 2015). In the gut many bacteria produce antimicrobial compounds and compete for nutrients and sites 
of attachment, thereby preventing colonization by pathogens, this is known as 
competitive-exclusion effect (Bull and Plummer 2014). Imbalance of gut microbial populations has important functional consequences and is implicated in chronic 
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gastrointestinal diseases such as Irritable Bowel Syndrome (IBS) and Inflammatory 
Bowel Disease (IBD)(Mai 2009). The use of high-throughput sequencing has 
allowed the identification of a great number of bacteria including uncultivable 
bacteria, with these techniques 395 bacterial phyla has been identified in the human gut to date. Most of the inferred organisms were anaerobes members of the Firmicutes and Bacteroidetes phyla and Proteobacteria (including Escherichia 
coli) and Actinobacteria phyla are found in small proportion, which is no surprising for anaerobes facultative species in the strict anaerobic environment of the colon 
(Eckburg, Bik et al. 2005). 
The integrity of the epithelial gastrointestinal tract is an important defense against 
bacterial pathogens, thus there is high rate of epithelial cell turn over to maintain 
the gastrointestinal epithelial integrity (Kim, Ashida et al. 2010). Throughout 
the gastrointestinal tract there are also specialized secretory cells responsible to produce a mucus layer of mucin glycoproteins and antimicrobial compounds to protect the epithelial surface from commensal bacteria of the microbiota and 
specialized bacterial pathogens (Ribet and Cossart 2015). Resident microbiota is 
important to induce mucus biosynthesis, the cell turnover and the formation of 
tight junctions (TJs) between cells (Kim, Ashida et al. 2010, Ribet and Cossart 2015). 
Commensal bacteria do not generally produce disease but in certain conditions 
like mucosal surface damage, they can become opportunistic pathogens and 
produce disease (McGuckin, Linden et al. 2011).  Interestingly bacterial pathogens have acquired mechanisms to cross host barriers and produce disease despite the 
defense mechanisms of the host (Kim, Ashida et al. 2010). 
2. Enteric bacterial pathogens
Enteric bacterial pathogens have evolved virulence traits that enable them to 
colonize the intestinal tract, adhere to or efface the epithelium, deliver enterotoxins and invade intestinal epithelial cells.  Using these mechanisms bacterial pathogens can disrupt intestinal functions and cause malabsorption or diarrhea and in some cases cross the intestinal epithelial barrier and get deeper tissues and induce 
systemic disease (Guerrant, Steiner et al. 1999). The bacteria pathogens of the genus 
Salmonella, Shigella and Listeria are enteric pathogens that can invade the cells lining the surface of the intestine and replicate inside them and later disseminate 
in the host (Mastroeni and Grant 2011, Ribet and Cossart 2015). Most Escherichia 
coli strains are harmless and commensal inhabitants of the gastrointestinal tract. 
Acquiring specific virulence factors, like pathogenicity island (PAI), prophages 
(PPs) and plasmids, certain isolates may become highly adapted pathogens able to 
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induce a range of diseases, from gastroenteritis to extraintestinal infections of the 
urinary tract, bloodstream and central nervous system (Croxen and Finlay 2010). 
Urinary tract infections (UTIs) are the most common extraintestinal infections 
produce by the so-called uropathogenic E. coli (UPEC) strains. Among the intestinal pathotypes of E. coli, which are able to cause disease in healthy human, there are the noninvasive enteropathogenic E. coli (EPEC), enterohaemorrhagic E. coli (EHEC), 
enterotoxigenic E. coli (ETEC) and enteroaggregative E. coli (EAEC) and also there 
is an invasive pathotype, which is able to replicate inside epithelial cells, named enteroinvasive E. coli (EIEC) (Kaper, Nataro et al. 2004). 
3. Enteropathogenic Escherichia coli (EPEC)
Enteropathogenic E. coli (EPEC) was the first pathotype of E. coli to be associated 
with human disease, it is an important category of diarrheagenic bacteria causing 
acute and chronic diarrhea in infants (Kaper, Nataro et al. 2004). The low microbial density of the small bowel caused by the forceful peristalsis in this part of the 
intestine is overcome by EPEC, which can successfully colonize the small intestine 
of humans (Hicks, Frankel et al. 1998, Tlaskalova-Hogenova, Stepankova et al. 
2004). EPEC primarily affects children younger than 2 years old, however some 
outbreaks of EPEC infection in healthy adults have been associated with large 
inoculum ingestion (Nataro and Kaper 1998). The mechanism of transmission 
of EPEC is the fecal-oral route, with contaminated hands, water, food or fomites 
serving as vehicles (Nataro and Kaper 1998). The reservoirs of EPEC infection 
are symptomatic and asymptomatic children and asymptomatic adults carriers, 
who handle young children (Nataro and Kaper 1998).  In the 1940s and 1950s 
EPEC was an important cause of diarrhea in developed countries with a 50% of 
mortality during outbreaks, but now the infection by EPEC in developed countries 
has a limited importance. In contrast, in low-income countries, EPEC is still an 
important cause infant diarrhea, representing between the 30% and 40% of the 
bacterial diarrheal pathogens in countries of South Africa and South America 
(Nataro and Kaper 1998).  EPEC strains include a diverse group of serotypes that 
are divided into typical (tEPEC) and atypical (aEPEC) strains based of the presence 
or the absence of a large virulence plasmid called EAF (EPEC adherence factor). 
In low-income countries tEPEC are the leading cause of infantile diarrhea while 
aEPEC seems to be the more important cause of diarrhea in developed countries 
(Trabulsi, Keller et al. 2002).
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3.1 EPEC pathogenesis 
The hallmark that defines EPEC infection is the Attachment and Effacement (A/E) 
lesion (Garmendia, Frankel et al. 2005). By adhering to intestinal epithelial cells, 
EPEC subvert cytoskeletal processes of the cell to produce a histopathological 
feature known as the A/E lesion. This lesion is characterized by the intimate 
attachment of the bacteria to the intestinal epithelial cells, induction of cytoskeletal 
changes including the accumulation of polymerized F-actin in pedestal-like 
structures underneath the attached bacteria, and microvilli surface disruption 
(effacement) (Kaper, Nataro et al. 2004). The A/E lesion is also characterized by microcolony formation and microvilli elongation in the area surrounding the 
microcolony (Knutton, Lloyd et al. 1987)(Figure 1). EPEC together with EHEC and 
Citrobacter rodentium (CR) are members of the A/E family since they colonize 
the gastrointestinal tract via the A/E lesion. EPEC and EHEC are important 
human pathogens while CR is a mouse-restricted pathogen (Mundy, Girard et al. 
2006).  The main difference between EPEC and EHEC pathogenesis is that EHEC 
produces enterotoxins. EHEC belongs to a group of pathogenic bacteria known as 
Shiga toxin-producing E. coli (STEC), which are define by their ability to produce 
Shiga Toxins (Stx). EHEC infection induces bloody diarrhea and the most serious 
complication of EHEC infection is the hemolytic-uremic syndrome (HUS). HUS is 
a microangiopathic hemolytic anemia characterized by disseminated capillary 
thrombosis and ischemic necrosis, which principally affect kidneys producing 
renal failure although it can affect other organs (Donnenberg and Whittam 2001).
Figure 1. A/E lesion induced by EPEC in human duodenal 
biopsy. Bacteria are attached in the enterocyte surface in pedestal 
like structures. See the microvilli effacement at the site of bacterial attachment. The microvilli are elongated in the edge of the microcolony. 
Transmission electron micrograph adapted from Knutton et al., 1987
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4. Key genetic and structural traits for A/E lesion formation
4.1 Locus of enterocyte effacement (LEE)
The ability of EPEC to induce A/E lesion is related with a pathogenicity island 
(PAI) of 35-kb called the locus of enterocyte effacement (LEE) (McDaniel, Jarvis 
et al. 1995). Homologues of LEE are also found in the other members of the A/E 
pathogens family EHEC and CR (Frankel, Phillips et al. 1998). The G+C content of the 
LEE is 38%, which is lower than the 51% of G+C content of the total E. coli genome 
and this indicates horizontal gene transfer of this pathogenicity island into E. coli 
from another species (Frankel, Phillips et al. 1998).  The LEE comprises 41 genes 
organized in five principal operons LEE1-LEE5 and several smaller transcriptional units (Figure 2) (Yerushalmi, Litvak et al. 2014). The LEE encodes all the structural 
genes necessary for the assembly of a type III secretion system (T3SS) injectisome 
on the bacterial cell envelope (McDaniel and Kaper 1997). The LEE also encodes 
transcriptional regulators (Ler, GrlR and GrlA), translocator proteins (EspA, EspB 
and EspD), six secreted effectors proteins (including the Translocated Intimin 
Receptor Tir), the outer membrane protein Intimin, molecular chaperones and a 
lytic transglycosilase (EtgA) (Dean, Maresca et al. 2005). The muramidase activity 
of the EtgA has been reported to enhance the levels of T3SS injectisome (Garcia-
Gomez, Espinosa et al. 2011). EtgA interacts with the injectisome component EscI 
to locally hydrolyse the peptidoglycan (PG) during assembly (Burkinshaw, Deng et al. 2015)
The mechanism of regulation of LEE is complex and depends on environmental 
conditions, quorum sensing (QS) and in several transcriptional regulators encoded 
in the LEE and outside the LEE (Garmendia, Frankel et al. 2005). The histone-like 
nucleoid-structuring protein (H-NS) is responsible of silencing the LEE operons 
during repressive conditions (Jobichen, Li et al. 2007). The first gene in LEE1 is 
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Figure 2. The Locus of enterocyte effacement (LEE) in EPEC. The LEE is constituted 
by five principal operons LEE1-LEE5 and other smaller transcriptional units. The 
LEE encodes all the structural proteins for the assembly of the T3SS injectisome, 
regulators for LEE expression, chaperones proteins and six effectors proteins.
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ler, encoding a positive regulator for all other LEE promoters; Ler functions as 
anti H-NS, to alleviate the H-NS-mediated repression (Yerushalmi, Litvak et al. 
2014). The expression of ler, and thus of LEE genes, is regulated both negatively 
and positively by a complex myriad of global regulatory proteins in response 
to different environmental signals (Bustamante, Villalba et al. 2011) .  The GrlA 
(global regulator of LEE activator) and GrlR (Global activator of LEE repressor), encoded by the grlRA operon within the LEE are involved in positive and negative regulation ler expression, respectively (Garmendia, Frankel et al. 2005).  Other positive regulators of ler expression like PerC (Plasmid-encoded-regulator C) 
and IHF (integrative host factor) overlaps with the GrlA activation depending on 
the growth conditions (Bustamante, Villalba et al. 2011).  Ler also regulates the 
expression of genes encoded outside the LEE like espC and non-LEE-effectors, such as nleA (Kaper, Nataro et al. 2004, Garcia-Angulo, Martinez-Santos et al. 2012). 
 4.2 The EPEC adherence factor (EAF) plasmid pMAR2
The prototypical EPEC strains E2348/69 is endowed of a 97kb plasmid called 
EAF for EPEC adherence factor, or pMAR2 (Iguchi, Thomson et al. 2009). The 
pMAR2 contains the operon perABC (plasmid encoded regulator). PerC regulates 
ler expression whereas PerA activates the expression of bfp, a 14-gene operon 
encoding for the bundle-forming pilus (BFP), a rope-like bundle of type IV pili 
(Stone, Zhang et al. 1996). BFP allows EPEC bacteria to form microcolonies in a 
pattern called localized adherence (LA) and also mediates the initial interaction of 
bacteria with host cells surfaces (Brinkley, Burland et al. 2006, Hyland, Sun et al. 2008). 
4.3 The Type III secretion system
The type III secretion system (T3SS) is a macromolecular transport apparatus 
that is used by many gram-negative bacteria  (e.g. Shigella, Yersinia, Salmonella) 
to translocate virulence proteins, also called effectors, into the cytosol of infected 
cells, subverting host cellular functions in profit of the infection (Ogino, Ohno et 
al. 2006). Since pathogens use this transport apparatus to inject proteins, this 
structure is also known as the injectisome. T3SS is closely related to the flagellum, which have given useful information about the structure and functionality of 
the T3SS (Erhardt, Namba et al. 2010). EPEC T3SS mediates the translocation of 
multiple effector protein during infection. Some of them are encoded in the LEE 
whereas others are encoded outside of the LEE being generally referred to as 
non-LEE effectors (Nle) (Garmendia, Frankel et al. 2005).  The T3SS of EPEC is 
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assembled for more than 20 proteins. This molecular nanomachine is composed 
of three portions: (i) the multiring basal body, which functions as a channel that spans the outer and inner membranes as well as the periplasmic space and houses 
the export apparatus, (ii) a hollow extracellular filamentous structure that forms 
a conduit to the host cell and (iii) a translocation pore formed in the host cell membrane by proteins known as translocators (Figure 3). 
The basal body is formed by a set of ring-like protein structures; the EscC, which 
forms the outer membrane (OM) ring, belongs to the members of the secretin superfamily that participates in the delivery of large molecules through the 
OM (Ogino, Ohno et al. 2006, Galan, Lara-Tejero et al. 2014). The EscD and the 
lipoprotein EscJ are forming the inner membrane (IM) ring. The EscI polymerizes 
to assemble the periplasmic inner rod of the basal body (Ogino, Ohno et al. 2006). 
The basal body has five proteins associated to the IM (EscR, EscS, EscT, EscU and 
EscV) that constitute the export apparatus (Romo-Castillo, Andrade et al. 2014). 
Associated to the basal body there is cytoplasmic ring formed by EscQ, that recruits 
the ATPase of the system called EscN, which is necessary to energize the protein 
translocation (Biemans-Oldehinkel, Sal-Man et al. 2011). The hollow filamentous 
needle structure is formed by polymerization of EscF to assemble the needle with 
an inner diameter of 2-3 nm, which is thought to allow the translocation of unfolded 
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Figure 3. Composition of the T3SS injectisome of EPEC. A. Schematic representation 
of the injectisome with the basal body (i), the extracellular filamentous structure 
(ii) and the translocation pore (iii). B. Electron micrograph of purified T3SS of EPEC 
showing that EspA filament is more than 600 nm long and 3D reconstruction of the 
EspA filament, showing the internal channel. Figures are adapted from Sekiya et al., 
2001 and Daniell et al., 2003
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proteins (Blocker, Jouihri et al. 2001, Wilson, Shaw et al. 2001).  Attached to the tip 
of the needle is the EspA filament, that is a helical tube of polymerized EspA, with 
more than 600 nm of length and central channel of 2.5 nm of diameter (Sekiya, 
Ohishi et al. 2001, Daniell, Kocsis et al. 2003). EspA enables the translocator proteins EspB and EspD to insert into the host cell membrane and assemble a pore 
of 3-5 nm to allow translocation of effector proteins into the cell (Ide, Laarmann et 
al. 2001, Luo and Donnenberg 2011).  
Type III secreted proteins, including translocator and effector proteins, have 
two dedicated domains recognized by the T3SS machinery: the N-terminal 
signal, spanning the first ~20 amino acid residues of these polypeptides, and 
the chaperone-binding domain located downstream from the N-terminal signal 
(Ghosh 2004, Arnold, Brandmaier et al. 2009, Munera, Crepin et al. 2010). These 
chaperones are essential to ensure efficient secretion and translocation of T3-
secreted proteins; CesAB, CesD and CesD2 are the corresponding chaperones of 
the EspA, EspB and EspD translocator proteins whereas CesT and CesF are the 
chaperones of effector proteins (Garmendia, Frankel et al. 2005, Thomas, Deng et 
al. 2005). The system has also two essential chaperones EscE and EscG that prevent 
premature polymerization of the EscF needle protein in the cytosol of the bacteria 
(Sal-Man, Setiaputra et al. 2013).
The assembly of the T3SS is a finely regulated process that requires many 
cytoplasmic and membrane associated proteins and chaperones (Monjaras 
Feria, Garcia-Gomez et al. 2012). At least two molecular switches participate in 
the assembly of functional injectisomes. EscU is an IM-associated protein with a 
cytoplasmic domain that is autocleaved, which induces a conformational change in 
EscU essential for the interaction with other T3SS components (Zarivach, Deng et 
al. 2008, Monjaras Feria, Garcia-Gomez et al. 2012). EscP, a weakly secreted protein 
of the T3SS, controls needle length by interacting with both EscF needle protein and EscI. EscP is suggested to sense when the needle is completed interacting with 
the cleaved cytoplasmic domain of EscU, inducing a conformation change in this 
protein that flicks a specificity switch to allow secretion of translocator (EspA, 
EspB, EspD) proteins by the export apparatus (Monjaras Feria, Garcia-Gomez et 
al. 2012). EscP also interacts with the chaperone CesT, which together with Tir 
and SepD-SepL complex, block secretion of effectors until the translocation pore is 
assembled in the host membrane (Monjaras Feria, Garcia-Gomez et al. 2012).  The 
SepD-SepL complex along with CesL, the chaperone of SepL, sense an undefined environmental signal when the translocator pore is assembled and this induces a 
second switch from translocator to effector secretion (Deng, Li et al. 2005, Younis, 
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Bingle et al. 2010). This second switch allows the injection of effector proteins 
into the host cell.  There is a hierarchy for the translocation of effectors, being 
Tir the first effector to be translocated in greater rate compared to the rest of 
effectors (Thomas, Deng et al. 2007, Mills, Baruch et al. 2013). Tir also influences 
the efficiency of injection of other effector proteins, likely due to the increased 
bacterial adhesion to host cells (Battle, Brady et al. 2014).
5. Model of EPEC pathogenesis 
EPEC pathogenesis is described in a three-stage model that includes: (i) localized 
adherence to host cells, (ii) signal transduction and intimate attachment, and (iii) subversion of host cellular processes.
5.1 Localized adherence to host cells
EPEC is endowed of a tight regulation of its virulence genes in response to 
environmental conditions. This regulation is less metabolically expensive for 
EPEC and avoids alerting the human immune system of the presence of EPEC 
prior to a successful colonization of the small intestine (Clarke, Haigh et al. 2003). 
Environmental conditions such as temperature (Yerushalmi, Litvak et al. 2014), 
the increase of pH in the small intestine compare to the stomach (Fallingborg 1999, 
Shin, Castanie-Cornet et al. 2001), the auto-inducer molecule 3 and hormones 
epinephrine and norepinephrine, which are released by the host during stress 
conditions, induce expression of EPEC virulence factors (Franzin and Sircili 2015). 
These signals are sensed by EPEC and integrated with its specific regulator PerC and with global transcriptional regulators of E. coli like IHF and H-NS between 
others, to induce expression of EPEC virulence genes like the bfp operon and the 
LEE, which participates in the initial attachment to the small intestine. 
At the beginning of the infection EPEC bacteria interact with the intestine-lining 
surface in a non-intimate manner. This contact is done mainly through the BFP 
that acts as an early adhesin in EPEC colonization of the human intestine. This 
initial adhesion is done by the interaction of the BFP with N-acetyl-lactosamine 
containing receptors in the host cell surface (Cleary, Lai et al. 2004, Hyland, Sun et al. 2008) (Figure 4). EspA also promote attachment to the enterocytes, albeit in 
a less efficient manner than the BFP (Cleary, Lai et al. 2004). In addition, flagella 
(Giron, Torres et al. 2002) and the E. coli common pilus (ECP) (Rendon, Saldana et 
al. 2007) and the lymphocyte inhibitory factor (LifA) (Badea, Doughty et al. 2003) 
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are also involved in this non-intimate interaction between the bacteria and the intestinal epithelium. 
5.2 Signal transduction and intimate attachment
Upon EPEC interaction with the enterocytes, EspB and EspD proteins are inserted 
into host cell membrane assembling the translocation pore (Guignot, Segura et 
al. 2015).  The complete assembly of the T3SS allows the injection of EPEC own 
receptor, which is a 78 kDa protein called translocated intimin receptor (Tir) 
(Kenny, DeVinney et al. 1997). Following translocation, Tir is phosphorylated 
in serine/threonine residues in its C-terminus by host kinases and this induces conformational shifts promoting the insertion of Tir into the apical host cell 
membrane (Kenny 2002). This insertion leaves the N- and C-terminal portions of 
Tir exposed to the cytosol of the host cell with helical transmembrane domains 
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Tir
Other effectors
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Figure 4. Localized adherence and intimate attachment of EPEC to the intestinal 
surface. At an early stage, EPEC interacts in a non-intimate manner with the 
intestinal surface mainly through the BFP and EspA filament. After assembly of 
the translocation pore, EPEC injects Tir. Ser/Thr phosphorylation of Tir induces its 
anchoring in the enterocyte plasma membrane, leaving TirM region exposed for the 
interaction with Intimin. Tir-Intimin interaction induces clustering and dimerization 
of Tir and this activates a signal cascade that generates actin polymerization and the pedestal formation underneath the attached bacterium and the intimate 
attachment of the bacteria to the enterocytes. Tir phosphorylation of residue Y474 
engages the host adaptor NcK, which later recruits N-WASP and WIP. N-WASP 
recruits ARP2/3 complex, which induces actin nucleation and polymerization
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traversing the host apical membrane and the central portion of about 100 aa known 
as TirM displayed on the surface of the cell (Lai, Rosenshine et al. 2013). TirM 
domain contains two α helices separated by a hairpin loop and this conformation 
mediates the interaction with a 94 kDa OM adhesin protein of EPEC called Intimin 
(Luo, Frey et al. 2000). Intimin comprises an N-terminal signal peptide for IM 
secretion through the Sec-translocon, followed by a short periplasmic LysM-
domain that binds the PG, a b-barrel domain that anchors the protein to the OM, 
and a extracellular segment composed by three immunoglobulin (Ig)-like domains 
and one C-terminal lectin-like domain, which mediates the interaction with TirM 
(Luo, Frey et al. 2000, Touze, Hayward et al. 2004, Leo, Oberhettinger et al. 2015). 
The C-terminal region of Intimin is also proposed to confer tissue specificity for 
A/E lesion formation in the small intestine by EPEC (Phillips and Frankel 2000, 
Reece, Simmons et al. 2001). Intimin forms homodimers in the OM mediated by 
the dimerization through the N-terminal region of periplasmic domains containing 
LysM (Leo, Oberhettinger et al. 2015). Intimin binding to Tir is proposed to induce 
clustering and dimerization of Tir in the host cell membrane, which is important to establish the intimate bacterial adherence and to initiate cellular signaling 
cascades for actin pedestal formation (Touze, Hayward et al. 2004, Lai, Rosenshine et al. 2013).  
Tir interacts with host proteins through its N- and C-terminal cytosolic domains, 
the N-terminal domain of Tir interact with focal adhesion proteins in a tyrosine 
phosphorylation independent manner stabilizing Tir interaction with the 
host cytoskeleton (Goosney, DeVinney et al. 2001). On the other hand, tyrosine 
phosphorylation of the C-terminal region of Tir by host cellular protein kinases is 
required for efficient actin polymerization.  Phosphorylation of residue Y474 is the 
most critical for focal actin assembly and is the major pathway to initiate pedestal 
formation (DeVinney, Puente et al. 2001). The pedestal formation requires a host 
adaptor protein called NcK, which contains and SH2 domain capable of binding a 
12 residues region that includes the critical phosphorylated Y474 (Campellone, 
Giese et al. 2002). NcK also contains three SH3 domains that may directly recruits 
the neural Wiskott-Aldrich Syndrome Protein (N-WASP) or indirectly through the 
intermediary adaptor, WASP Interacting Protein (WIP) (Lai, Rosenshine et al. 2013, 
Young, Clements et al. 2014). The N-WASP protein successively recruits and activates 
the actin nucleating ARP2/3 complex, which induces the actin nucleation and 
polymerization. Actin polymerization drives membrane protrusion and pedestal 
formation (Kalman, Weiner et al. 1999). There are also minor NcK independent 
mechanisms of actin pedestal formation, indicating redundant pedestal formation 
pathways. Most of this activity also requires Tir Y474, reaffirming its role as a key 
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residue for triggering actin assembly by Tir.  In the absence of Y474, residue Y454 
of Tir is critical for this minor NcK independent actin assembly (Campellone and 
Leong 2005)(Figure 4).
5.3 Subversion of host cellular processes 
Most EPEC strains remain extracellular in the small bowel during the infection and 
rely upon the T3SS to deliver effector proteins directly into the host cell to subvert 
numerous host cell functions (Donnenberg and Kaper 1992, Ochoa and Contreras 
2011). Some of the effector proteins are encoded within the LEE: EspF, EspG, 
EspH, Map, EspZ, Tir, plus the translocator pore-forming protein EspB that also 
has effector functions in the cells (Garmendia, Frankel et al. 2005, Iizumi, Sagara 
et al. 2007). Also important are non-LEE encoded effectors (Nle), EPEC serotype 
O127:H6 strain E2348/69 has 17 Nle effectors genes localized in integrative 
elements (IEs) and prophages (PPs) distributed around EPEC genome (Iguchi, 
Thomson et al. 2009, Deng, Yu et al. 2012). The majority of these effector proteins 
are multifunctional and have the ability to work together in redundant, synergetic 
or antagonistic relationships over the host cells in benefit of EPEC infection(Dean, 
Maresca et al. 2005). EPEC E2348/69 is the prototype strain most widely used 
worldwide to study EPEC infection, although there are other EPEC serotypes and 
strains with different repertoires of T3SS effectors (Iguchi, Thomson et al. 2009).
5.3.1 Actin cytoskeletal manipulation 
EPEC translocates effectors proteins that manipulate host actin cytoskeleton, 
in other to allow the progression of the infection (Alto, Shao et al. 2006, Wong, 
Raymond et al. 2012) (Figure 5). The effector protein Map belongs to a WxxxE 
family of bacterial effectors with the capacity to affect the Rho GTPase signaling 
pathways (Alto, Shao et al. 2006). Map functions as potent guanine-nucleotide 
exchange factor (GEF) for the Cdc42 Rho GTPase (Huang, Sutton et al. 2009). The 
activation of Cdc42 triggers a transient filopodia formation at bacterial attachment 
sites during early stages of EPEC infection (Berger, Crepin et al. 2009). Map also 
induces filopodia stabilization in a mechanism that involves indirect activation 
of the small Rho GTPase RhoA and RhoA-ROCK pathway (Berger, Crepin et al. 
2009). The Map-mediated Cdc42 signaling inhibits Tir-Intimin triggered pedestal 
formation (Kenny 2002). Tir antagonizes the Map-induced filopodia formation, in 
mechanisms that involve Intimin-Tir interaction, either because this interaction 
is propose to release a C-terminal encoded GAP-like activity to down-regulated 
Cdc42 function by stimulating its conversion to the GDP-bound inactive form and/
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or by the activation of Tir actin polymerization cascades (Kenny 2002, Kenny 2002, 
Berger, Crepin et al. 2009). The relevance of Map-mediated filopodia formation on cultured cells to in vivo infection is not yet known (Wong, Pearson et al. 2011). 
EspH also manipulates actin cytoskeleton of the infected cell. EspH down-regulates 
filopodia formation, while induces actin polymerization and pedestal elongation in 
an Nck-independent recruitment of WIP and N-WASP (Tu, Nisan et al. 2003, Wong, 
Raymond et al. 2012). Infection with EPEC overexpressing EspH indicates that EspH 
is a potent inducer of cytotoxicity and cell detachment. EspH induces disassembly 
of focal adhesions (FAs) concomitantly with actin disruption, generating a cell 
rounding phenotype (Wong, Clements et al. 2012). The multifunctional effector 
EspF also induces pedestal maturation, through the recruitment of junctional 
proteins into the pedestal (Peralta-Ramirez, Hernandez et al. 2008).
5.3.2 Alterations of epithelial function
The intestinal epithelium acts as a physical barrier separating luminal environment 
and subepithelial tissues. The formation of intercellular TJs is important to maintain 
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Figure 5. Actin manipulation by EPEC effector proteins. Map induces a 
transient filopodia formation at the beginning of the infection at the site of 
bacterial attachment and inhibits pedestal formation. Tir and EspH antagonize this 
filopodia formation and induce actin polymerization and pedestal formation. EspH 
induces disassembly of Focal Adhesions (FAs). EspF induces pedestal maturation.
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this intestinal barrier function (Dean and Kenny 2004).  The microvilli surface of the intestinal epithelium increases the absorptive area of the intestine and contains 
a broad of digestive enzymes, nutrient and electrolyte transporters (Lapointe, 
O’Connor et al. 2009). During EPEC infection the cytoskeletal rearrangement 
to induce pedestal formation results in microvilli destruction, which severely 
diminish the absorptive capacity of the infected intestinal surface, driving to loss 
of water and consequent diarrhea (Buret, Olson et al. 1998). The rapid onset of 
severe watery diarrhea prior to the full A/E lesion formation is suspected to be 
mediated by an active secretory mechanism in which T3SS effectors affect water 
and ion transport (Lapointe, O’Connor et al. 2009) (Figure 6). 
The cooperative action of Tir, Map and EspF inhibits the sodium-D-glucose 
transporter (SGLT-1), the major water pump of the small intestine, responsible for 
about 70% of the total fluid uptake (Dean, Maresca et al. 2006). The multifunctional 
effector EspF reduces expression of the sodium hydrogen exchanger (NHE3), 
which reduces the Na+ absorption. It is also reported that Map through a TRL (Thr-
Arg-Leu) motif is involved in a protein complex that include the NHEF1 (sodium 
hydrogen exchanger regulatory factor 1) and induce phosphorylation of the NHE3 
leading to its inhibition (Simpson, Shaw et al. 2006). Since water osmotically moves 
towards areas of higher salt concentrations, changes in Na+ absorption leads to 
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Figure 6. EPEC effector proteins altering epithelial cell function and 
inducing water loss and diarrhea. Tir, Map and EspF inhibit the sodium-
D-glucose transporter (SGLT-1). EspF reduces expression of the sodium 
hydrogen exchanger (NHE3). EspG and EspF induce mislocalization 
of aquaporins (AqP). EspG1/EspG2 alter membrane targeting of Cl-/
OH- exchanger. EspF, Map, NleA, EspG1 and EspG2 disrupt the tight 
junctions (TJ). EspB, Tir, EspF and Map induce microvilli effacement.
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diarrhea (Hecht, Hodges et al. 2004, Hodges, Alto et al. 2008). EspG1 and EspG2 
proteins alter the membrane targeting of Cl-/OH- exchanger (DRA), resulting 
in reduce Cl- uptake and its accumulation in the lumen, which also drives water 
loss. This effect seems to be mediated by EspG/EspG2 disruption of microtubular 
network (Gill, Borthakur et al. 2007). EspF and EspG induce mislocalization of 
aquaporins (AQP), reducing the water absorption from the intestinal lumen 
(Guttman, Samji et al. 2007, Croxen and Finlay 2010). The translocator protein 
EspB interacts with myosin inhibiting the interaction of myosin-actin filaments 
and inducing microvillus effacement (Iizumi, Sagara et al. 2007). Tir, EspF and Map also induce microvillus effacement and this disruption of the brush border surface 
certainly exacerbate EPEC diarrhea (Dean, Maresca et al. 2006).  Other effectors 
like EspF and Map act synergistically disrupting TJs, inducing mislocalization of 
the transmembrane TJs protein occludin (McNamara, Koutsouris et al. 2001, Dean 
and Kenny 2004). EspG1/EspG2-induced microtubule-disruption contributes to 
TJs disruption by a shift in localization of TJ proteins to the cytosol and the NleA 
effector protein also disrupts TJs blocking the delivery of new TJs proteins (Kim, 
Thanabalasuriar et al. 2007, Thanabalasuriar, Koutsouris et al. 2010, Glotfelty, 
Zahs et al. 2014). The TJs disruption done by these effectors increase intestinal 
permeability, and this could contribute to EPEC-induced diarrhea (Croxen, Law et al. 2013). 
5.3.3 Subversion of host immune pathways
EPEC infection is characterized by a weak inflammatory response (Dean and Kenny 
2009). Some LEE effectors proteins and a bigger group of Nle effectors overcome 
the host immune response, which favors bacterial survival (Figure 7).  
5.3.3.1 Counteracting phagocytosis
Phagocytosis is a key mechanism of the innate immune system to fight against 
pathogens (Santos and Finlay 2015). Several effectors of EPEC counteract 
phagocytosis. EspB interfere with phagosome closure and prevent EPEC 
internalization in macrophages by interaction with myosin (Iizumi, Sagara et al. 
2007). EspF prevents the phosphatidylinositol-3 kinase (PI3K) dependent F-actin 
rearrangement required for phagocytosis (Quitard, Dean et al. 2006). EspH binds 
mammalian Rho guanine nucleotide exchange factors (RhoGEFs) preventing actin 
reorganization necessary to induce phagocytosis. Lastly EspJ prevents opsono-
phagocytosis (Marches, Covarelli et al. 2008, Dong, Liu et al. 2010). 
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5.3.3.2 Modulation of inflammatory signaling pathways
The PAMPs (pathogens-associated molecular patterns) are recognized by intestinal 
epithelial cells, through PRRs (pattern recognition receptors), this interaction 
triggers the activation of proinflammatory pathways such as; the nuclear factor-
κB (NF-κB) and the mitogen-activated protein kinase (MAPK) (Takeuchi and Akira 
2010). The NF-κB refers to transcription factor complexes, which include c-Rel, 
RelB, p65, p50, and p52.  In unstimulated cells, homodimers or heterodimers 
of NF-κBs proteins (being p65/p50 the most abundant) are maintained in an 
inhibited state in the cytoplasm bound to IκB (Muhlen, Ruchaud-Sparagano et 
al. 2011). Following host cell detection of PAMPs by PRRs, a signaling cascade is 
initiated leading to activation IκB kinase (IKK) complex, which phosphorylates IκB 
targeting it for proteasome degradation (Liou 2002, Takeuchi and Akira 2010). 
IκB degradation frees p65/p50 allowing them to translocate to the nucleus, where 
they activate transcription of cytokine genes including IL-1β, IL-6, IL-8 and TNF-α 
(Pahl 1999). 
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Figure 7. Schematic representation of multifunctional and overlapping 
effectors to control host immune response. NF-κB proinflammatory pathway is 
activated by NleF and NleH2 and is inhibited by NleE, NleB, NleH1, Tir and NleC. 
NleC and NleD inhibit the MAPK proinflammatory pathway. EspF, EspJ, EspH, 
EspB prevent macrophage phagocytosis. NleA disrupts inflammasome activation 
and LifA inhibits IL-2 and IL-4 production and lymphocyte proliferation. EspF 
and Map induce intrinsic apoptosis and EspZ counteracts these effects stabilizing 
mitochondrial membrane potential. NleH1/NleH2 and NleF counteract the 
intrinsic apoptosis and NleF, NleD and NleB counteract the extrinsic apoptosis. 
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It has been reported that during early stage of infection the injection of NleF by 
EPEC induces NF-κB activation and expression of IL-8 (Pallett, Berger et al. 2014). 
Also NleH2 induces NF-κB activation (Pham, Gao et al. 2012). Nevertheless, EPEC 
translocates several effectors that target the proinflammatory pathways of the cell, 
and this counteracts the proinflammatory effect of EPEC to allow progression of the 
infection (Wong, Pearson et al. 2011). Tir also interferes with the NF-κB signaling 
pathway; the interaction of Tir with SPH-2 cellular tyrosine phosphatase facilitates 
the recruitment of TNF receptor-associated factor (TRAF6) and inhibits the 
downstream cytokine production (Yan, Quan et al. 2013). NleE inhibits the TNF-α 
and IL-1β-induced activation of NF-κB by preventing the proteasome degradation 
of IκB. The NleE-mediated stabilization of IκB prevents p65 nucleation and the 
downstream cytokine expression (Newton, Pearson et al. 2010). NleB inhibits the 
TNF-α-induced activation of NF-κB also preventing the IκB degradation (Newton, 
Pearson et al. 2010). NleB has a N-acetylglucosamine (GlcNAc) transferase activity 
that specifically glycosylates the death domains of proteins involved in death 
receptor signaling as TRADD, which block the signaling of these adaptors, thereby 
interrupting TNF-α-induced activation of NF-κB (Li, Zhang et al. 2013). NleH1 
and NleH2 EPEC effectors interact with the ribosomal protein S3 (RPS3), which 
is a non-Rel subunit of NF-κB complexes. NleH1 inhibits nuclear translocation 
of RPS3, and blocks the NF-κB activation after TNF-α stimulation (Pham, Gao et 
al. 2012). NleC is a zinc metalloprotease that directly cleaves p65 subunit in its 
N-terminal domain (Yen, Ooka et al. 2010). NleC mediates proteolysis of p65 late in 
infection and results in proteasome-independent degradation of p65, suppress the 
subsequent NF-κB activation, and impair secretion of cytokines (Muhlen, Ruchaud-
Sparagano et al. 2011). NleC degrades free p65 and also IκB-bound p65, although 
it has been proposed that free p65 is the primary target (Baruch, Gur-Arie et al. 
2011, Santos and Finlay 2015). NleC also targets p50 and IκBα for proteasome-
independent degradation (Muhlen, Ruchaud-Sparagano et al. 2011). NleC and NleD 
interfere with the MAPK proinflammatory pathway resulting in decrease cytokines 
secretion (Baruch, Gur-Arie et al. 2011, Sham, Shames et al. 2011). Other effectors 
block the host immune response through other mechanisms. NleA subdues host IL-
1β secretion in a NF-κB-independent manner; NleA interaction with NLRP3 (Nod-
like Receptor 3) disrupts the posterior inflammasome activation (Yen, Sugimoto et al. 2015). The product of the lifA gene, which encodes a toxin called lymphostatin, 
inhibits IL-2 and IL-4 production and lymphocyte proliferation and has also been 
reported to be injected by the T3SS (Klapproth, Scaletsky et al. 2000, Deng, Yu et al. 2012).  
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5.3.3.3 Regulation of cell survival and apoptosis
The epithelial cell death response to microbial infection is pivotal for pathogens 
and the host. Pathogens that are colonizing the epithelium need to prevent cell 
death to preserve their replicative foothold; by contrast, the host needs to eliminate 
infected cells in order to minimize tissue damage (Kim, Ashida et al. 2010). During 
infection of intestinal epithelial cells, surfaces properties of EPEC are recognized 
by cell surface death receptors and induce extrinsic apoptotic pathways, while 
T3SS effectors (Map and EspF) trigger intrinsic apoptotic pathways (Wong, 
Pearson et al. 2011, Santos and Finlay 2015) (Figure 7). EspF is targeted to the 
mitochondria by an N-terminal target sequence and destabilizes mitochondrial membrane potential leading to cytochrome c release, activation of caspases and 
downstream intrinsic apoptosis (Nougayrede and Donnenberg 2004, Nagai, 
Abe et al. 2005). Map also localizes in the mitochondria through a N-terminal 
mitochrondria targeting sequence, inducing mitochondria disruption, cytochrome 
c release and the subsequent induction of apoptosis (Kenny and Jepson 2000, Ma, 
Wickham et al. 2006). Interestingly, early stages of apoptosis can be observed 
during EPEC infection, but late-stages are not evident, and this is because EPEC 
translocate effector proteins that antagonize these pro-apoptotic effects (Crane, 
McNamara et al. 2001, Wong, Pearson et al. 2011). NleD and NleB interfere with 
the pro-apoptotic death receptor signaling and disrupt the downstream extrinsic 
apoptosis (Baruch, Gur-Arie et al. 2011, Pearson, Giogha et al. 2013). NleH1/NleH2 
inhibit caspase-dependent intrinsic apoptosis in infected host cells, reducing 
levels of active caspase-3 and thereby preventing cell death. This ability appears 
to be largely due to the interaction of NleH1 and NleH2 with the anti-apoptotic 
protein, Bax inhibitor-1 (BL-1)(Hemrajani, Berger et al. 2010, Royan, Jones et al. 
2010). EspZ also inhibits intrinsic apoptosis and promotes host cell survival. EspZ 
localizes in the mitochrondria and stabilizes mitochondrial membrane potential, 
counteracting cytotoxicity effects of Map and EspF, preventing the release of cytochrome c and the subsequent induction of intrinsic apoptosis (Roxas, Wilbur 
et al. 2012).  EspZ also localizes to the cytoplasmic face of the plasma membrane at the site of bacterial attachment and interact with EspD translocator. It has been 
proposed that EspZ prevents cell death by downregulating protein translocation; 
consistently an EPEC ΔespZ mutant was highly cytotoxic (Berger, Crepin et al. 
2012). NleF effector protein directly inhibits caspases involved in both intrinsic 
and extrinsic apoptosis pathways, including caspases-4, -8 and -9 (Blasche, Mortl 
et al. 2013). EPEC effectors are injected in a regulated manner to guarantee the 
infection, such as the prosurvival effector EspZ is translocated earlier, whereas the 
pro-apoptotic EspF and Map follows later, the translocation order indicates that 
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EspZ is able to act first preventing cell death (Mills, Baruch et al. 2008).
6. Models to study EPEC infection
Because EPEC is a human pathogen primarily affecting infants, experimental 
models are needed to study the infection process. The majority of the information 
about EPEC infection and induction of actin pedestal formation have been obtained from in vitro tissue culture cell models and most of these culture cell lines 
are nonpolarized cell lines and are not from intestinal origin (Knutton, Baldwin 
et al. 1989, Berger, Crepin et al. 2009, Berger, Crepin et al. 2012). Therefore, 
the physiological relevance of the finding discovered in culture cell lines needs 
confirmation in more biologically relevant models. Hence, some studies have been carried out in adults human volunteers but they used a large bacterial doses 
that represents an artificial situation (Donnenberg, Tacket et al. 1993, Nataro 
and Kaper 1998). Although EPEC does not infect most laboratory animal models, several studies have reported that mice were susceptible to infection by E. coli 
pathogens(Hecht, Marrero et al. 1999, Savkovic, Villanueva et al. 2005). Thus, a 
study indicates that mice infection by EPEC induced intestinal inflammation and some microvillus effacement but without intimate bacterial attachment with the 
mice intestinal surface (Savkovic, Villanueva et al. 2005). By contrary, other studies 
indicate that EPEC do not induce A/E lesion in the mouse intestine and that EPEC 
establishes a commensal relationship with the mouse host (Frankel, Phillips et al. 
1996, Klapproth, Sasaki et al. 2005, Mundy, Girard et al. 2006). Hence, the use of 
adult mice infection model is questionable. The A/E lesion induced by EPEC has also been studied in ligated intestinal loops of pigs and rabbits and in gnotobiotic 
pigs and newborn mice, which lack a mature microbiome and immune system, 
but except the pig model none of these models fully reproduce the phenotype of 
A/E lesion observed in the human intestine (Moon, Whipp et al. 1983, Dupont, 
Sommer et al. 2016). Importantly, ex vivo infection of human cultured intestinal 
biopsies (IVOC of In Vitro Organ culture) with EPEC induces A/E lesions that are 
undistinguishable of those observed in intestinal biopsies of patients with EPEC 
diarrhea. Because of this, the IVOC assay has been proposed as a model to study 
EPEC infection in closer circumstances to natural EPEC infection (Knutton, Lloyd et 
al. 1987). Several studies have also revealed that conclusions made during infection of cultured cell lines in vitro cannot be completely extrapolated to infection of IVOC. 
For instance, some EPEC strains failed to induce fluorescence actin staining (FAS) 
on Hep-2 cells but produced typical A/E lesions on human IVOC (Knutton, Shaw 
et al. 2001). In addition, an EPEC strain expressing TirY474S, which disrupts the 
most critical phosphorylation residue for actin assembly in cell culture, displayed 
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classical A/E lesion during IVOC infections of human duodenal biopsies (Schuller, 
Chong et al. 2007). Hence, infection studies with human IVOC may be closer to the actual in vivo situation in human intestine. 
7. EPEC treatment and vaccines
The primary goal to treatment of EPEC diarrhea is to prevent dehydration by 
correcting body fluid and electrolytes imbalance.  Oral rehydration may be sufficient 
for milder cases, but more severe cases require parental rehydration (Nataro and 
Kaper 1998). Persistent infections may require the use of antibiotics. Antibiotics 
have been useful in many cases, but several clinical isolates exhibiting a high 
degree of resistance to standard antibiotics (Hill, Phillips et al. 1991, Subramanian, 
Selvakkumar et al. 2009, Croxen, Law et al. 2013). EPEC antibiotic-resistant strains 
have been found across many continents, with reported cases in Mexico (Gomez-
Aldapa, Cerna-Cortes et al. 2016), Brazil (Scaletsky, Souza et al. 2010), United 
Kingdom (Jenkins, Smith et al. 2006), Singapore (Lim, Ngan et al. 1992) and the 
United States (Moyenuddin, Wachsmuth et al. 1989). EPEC is the etiological agent 
of important diarrhea, however there are not vaccines available to control its 
spread. In a study conducted with adult human volunteers, they demonstrated that 
previous infection with EPEC E2348/69 reduces the severity of subsequent illness 
upon reinfection with the homologous strain. No evidence of protective immunity 
was observed, but it was probably because of the high inoculum dose necessary to 
induce efficient colonization in adults (Donnenberg, Tacket et al. 1998). Antibodies 
from maternal colostrum and serum samples have been shown to recognize EPEC 
surface antigens such as BFP, Intimin, and to the secreted proteins EspB and EspA 
(Parissi-Crivelli, Parissi-Crivelli et al. 2000).  Therefore these virulence proteins 
are good candidates for vaccine development against EPEC infection. Human 
volunteer studies have shown that 36% of individuals who ingested an EPEC∆eae 
strains still developed diarrhea (Donnenberg, Tacket et al. 1993). Other study 
with adult volunteers, 10% of individuals who ingest ∆espB mutant developed 
diarrhea compared to 90% of diarrhea in individuals who ingested the WT strain 
(Tacket, Sztein et al. 2000). In a study conducted with ∆bfp mutant, it was still able 
to colonize and cause diarrhea in some cases although it was less virulent than 
the WT strain (Bieber, Ramer et al. 1998). These data indicate that more than one 
antigenic factor need to be deleted in EPEC to prevent infection. An alternative 
strategy would be to develop an attenuated EPEC strain that fails to cause diarrhea, but that keeps adherence factors to attach to the epithelial intestine surface and all antigens to induce an effective protection against the infection.
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Pathogenic bacteria such as EPEC have evolved to acquire virulence factors to 
compete with the commensal flora and to overcome the host immune response. Among these skills the acquisition of the T3SS allows EPEC to translocate effector 
proteins into the host-cell and subvert cellular functions toward infection. Com-mon research on EPEC effectors is conducted by generating loss of function mutant strains that are complemented with plasmids overexpressing these effectors, or by the ectopic expression in the host cell of individual effector proteins after plas-
mid transfection. Both situations are prone to effector overexpression, producing non-physiological levels of effectors inside the host cell, which could alter effector 
activities. In addition, effectors often have synergistic and overlapping functions that cannot be fully appreciated by single mutations and individual transfection ex-
periments. Hence, it will be interesting for EPEC research the availability of mutant strains lacking all the effectors of the T3SS and that would enable the control re-
insertion of specific genes encoding effector protein(s) in the chromosome, allow-ing the study of these effectors at physiological levels and without the background 
activity of other effector proteins. Lastly, generation of these effector mutant EPEC strains, which are expected to be highly attenuated in virulence, will be of interest 
for development of an EPEC vaccine and for the therapeutic delivery of specific 
proteins in human intestine. 
Thus, the objectives of this thesis are:
1. To evaluate the applicability of the markerless gene deletion strategy for the ap-
propriate genome manipulation of EPEC serotype O127:H6 strain E2348/69. 
2. To generate an EPEC strain lacking of all known effector proteins of the T3SS, 
preserving the correct assembly and function of the T3SS injectisome. 
3. To identify the minimum set of effectors that EPEC needs to induce actin-pedes-
tal formation into HeLa cells. 
4. To translocate individual effector proteins into HeLa cells from the effector mu-
tant EPEC strains and to evaluate the phenotype elicited by these effectors.
5. To infect human intestinal biopsies with the effector mutant EPEC strains in or-
der to identify the essential effectors needed to induce the A/E lesion formation in 
the mucosal tissue.  
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1.  Bacterial strains 
The bacterial strains used in this work are listed in Table 1.
Table 1. Bacterial strains used in this workName Genotype and relevant properties ReferenceDH10B-T1R (F- λ-) mcrA Δmrr-hsdRMS-mcrBC 
φ80lacZDM15 ΔlacX74 recA1 endA1 araD139 
Δ(ara, leu)7697 galU galK rpsL (StrR) nupG 
tonA
Thermo Fisher 
(Durfee, Nel-son et al. 
2008)
BW25141
(F- λ-) Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
Δ(phoB-phoR)580, galU95, ΔuidA3::pir, recA1, 
endA9(del-ins)::FRT, rph-1, Δ(rhaD-rhaB)568, 
hsdR51.
(Datsenko and 
Wanner 2000)
CC118 lpir
∆(ara-leu) araD ∆lacX74 galE galK phoA20 thi- 
rpsE rpoB argE(Am) recA1, lpir
(Herrero, de 
Lorenzo et al. 
1990)
EPEC EPEC 0127:H6 E2348/69
(Iguchi, Thom-son et al. 
2009)
EPEC∆escN E2348/69 ∆escN This work
EPEC∆map E2348/69 ∆map This work
EPEC∆map.
espG
E2348/69 ∆map ∆espG This work
EPEC∆map.
espGF
E2348/69 ∆map ∆espG ∆espF This work
EPEC9 E2348/69 ∆map ∆espG ∆espF ∆espH This work
EPEC8 EPEC9 ∆IE5 This work
EPEC7 EPEC8 ∆IE6 This work
EPEC6 EPEC7 ∆IE2 This work
EPEC5 EPEC6 ∆PP2 This work
EPEC4 EPEC5 ∆PP3 This work
EPEC3 EPEC4 ∆PP4 This work
EPEC2 EPEC3 ∆PP6 This work
EPEC1 EPEC2 ∆espZ This work
EPEC0 EPEC1 ∆tir This work
EPEC2-LEE+ EPEC2+(map+espH+espF+espG) This work
EPEC7∆lifA-like EPEC7 ∆lifA-like This work
EPEC7∆nleE EPEC7 ∆nleE This work
EPEC2+map EPEC2+map This work
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EPEC1+map EPEC1+map This work
EPEC0+map EPEC0+map This work
EPEC2+nleC EPEC2+nleC This work
EPEC1+nleC EPEC1+nleC This work
EPEC0+nleC EPEC0+nleC This work
EPEC2+espH EPEC2+espH This work
EPEC1+espH EPEC1+espH This work
EPEC0+espH EPEC0+espH This work
EPEC2∆eae EPEC2 ∆eae This work
EPEC1∆eae EPEC1 ∆eae This work
EPEC∆grlR E2348/69 ∆grlR::AmpR.FRT This work
2. Conditions for bacterial growth
Bacteria were grown at 37oC in Luria Bertani (LB) agar plates (1.5% w/v) (Bertani 
1951), in liquid LB medium or in Dulbecco’s Modified Eagle’s medium (DMEM). 
When needed for plasmid or strain selection, antibiotics were added at the following 
concentrations: ampicillin (Amp) 150 µg/ml, except for strains expressing the Amp 
resistance gene from their chromosome, which were selected with Amp at 75 μg/
ml; chloramphenicol (Cm) 30 µg/ml; kanamycin (Km) 50 µg/ml; tetracycline (Tc) 
10 µg/ml; spectinomycin (Sp) 50 µg/ml.
2.1 Induction of the T3SS in EPEC
EPEC strains were grown overnight (o/n) static at 37oC in a flask with 5 ml of liquid 
LB, unless other wise indicated. Next day, cultures were diluted to a 0.05 OD
600
 in 5 
ml of LB/DMEM in a well capped Falcon tubes (BD Biosciences) and incubated in 
agitation (180 rpm) for 4 h for the expression of the T3SS, these cultures were used 
for the analysis of the T3-secreted proteins to the supernatant. For the infection of 
cell cultures with EPEC strains, the o/n LB bacteria cultures were diluted 1:50 in 5 
ml of DMEM serum free in 50 ml Falcon tubes and were grown at 37 oC and 5% CO2, 
with the lid open in static during 2.5 h, unless otherwise indicated. EPEC strains 
harbouring map, tir and nleC for the analysis of individual translocation of Map, Tir 
and NleC were grown o/n with agitation at 37oC in a 30 ml tube SterilinTM with 5 
ml of liquid LB. The o/n LB bacteria cultures were diluted 1:100 in 5ml of DMEM 
serum free in 30 ml tube SterilinTM and were grown at 37 oC and 5% CO2, with the 
lid open and in static during 3 h. 
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Alternatively EPEC strains harbouring TcR plasmids used for the β-lactamase 
assay, were grown o/n at 37 oC with agitation at 180 rpm with Tc and next day 
were diluted to 0.05 OD
600
 in 4 ml of DEMEM without Tc and grown in 6-well tissue 
culture plates (Falcon) during 3 h, at 37 oC and 5% CO2.
3. DNA constructs
E. coli DH10B-T1R strain was used as host for the cloning and propagation of 
plasmids with the pBR or pSC101-ts origins of replication. In the case of suicide 
pGE derivatives, harbouring the R6K-ori, the E. coli strains BW25141 or CC118-
λpir were used, these strains express the π protein needed for plasmid replication 
(Stalker, Kolter et al. 1982). 
Plasmids employed in this study are summarized in Table 2. Standard methods 
of DNA manipulation were used (Ausubel F.M. 2002).  When indicated, DNA was 
synthesized by GeneArt (Life Technologies). All DNA constructs were verified 
by DNA sequencing (Secugen or StabVida). Oligonucleotides used in this work 
were obtained from Sigma and are described in Table 3. PCRs were performed 
with the Taq DNA polymerase (Roche, NZyTech) for standard amplifications in 
screenings and with the proofreading DNA polymerase Herculase II Fusion (Agilent 
Technologies) and Vent DNA polymerase (NEB) for cloning purposes. Details of plasmid constructions are described below.
Table 2. Plasmids used in this workPlasmid Relevant genotype and features Refer-ence Primers
pCX340 (TcR) pBR ori, ptrc promoter, for fu-
sions to the β-lactamase 
(Char-pentier 
and Os-wald 
2004)pEspF1-20Bla
pCX340 derivative; EspF secretion 
signal, residues 1-20 fused to the 
β-lactamase
(Blanco-
Toribio, 
Muylder-mans et 
al. 2010)
pACBSR (CmR) p15A ori, pBAD promoter, I-
SceI endonuclease and λ Red genes
(Herring, Glasner et al. 
2003)
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pACBSR-Sp (SpR) p15A ori, pBAD promoter, I-
SceI endonuclease and λ Red genes
This work
pGETS (KmR); pSC101-ts ori, polilynker 
flanked two I-SceI restriction sites This work 102, 103
pGE (KmR) R6K-ori, polylinker flanked by two I-SceI restriction sites (Pinero-Lambea, Bodelon et al. 
2014)
pGE∆map pGE derivative; with homology 
regions flanking the map gene of 
EPEC
This work GeneArt, Life Technologies 
XhoI-SphI
pGE∆espG pGE derivative; with homology 
regions flanking the espG gene of 
EPEC
This work 3, 4, 5, 6
pGE∆espF pGE derivative; with homology 
regions flanking the espF gene of 
EPEC
This work GeneArt, Life Technologies 
XhoI-SphI
pGE∆espH pGE derivative; with homology 
regions flanking the espH gene of 
EPEC
This work 11, 12, 13, 14
pGE∆IE5 pGE derivative; with homology 
regions flanking cluster of effec-
tor genes in IE5 (espC and espG) of 
EPEC
This work 15, 16, 17, 18
pGE∆IE6 pGE derivative; with homology 
regions flanking cluster of effector 
genes in IE6 (espL, nleB, nleE, efa1/
lifA) of EPEC
This work 21, 22, 23, 24
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pGE∆IE2 pGE derivative; with homology 
regions flanking cluster of effector 
genes in IE2 (efa1/lifA, nleE, nleB*, 
espL*) of EPEC
This work 27, 28, 29, 30
pGE∆PP2-Amp.FRT pGE derivative; with AmpR (flanked by FRTs) between the homology 
regions flanking cluster of effector 
genes in PP2 (nleH, Cif*, espJ) of 
EPEC
This work 33, 34, 35, 36, 57, 59
pGE∆PP3-Amp.FRT pGE derivative; with AmpR (flanked by FRTs) between the homology 
regions flanking nleJ in PP3 of EPEC
This work 39, 40, 41, 42, 57, 59
pGE∆PP4-Amp.FRT pGE derivative; with AmpR (flanked by FRTs) between the homology 
regions flanking cluster of effec-
tor genes in PP4 (nleG, nleB, nleC, 
nleH*, nleD) of EPEC
This work 45, 46, 47, 48, 57, 59
pGETS∆PP6-
Amp.FRT
pGETS derivative; with AmpR 
(flanked by FRTs) between the ho-
mology regions flanking cluster of 
effector genes in PP6 (nleA/espL, 
nleH, nleF, espO) of EPEC
This work 51, 52, 53, 54, 58, 59
pGE∆PP2 pGE derivative; with the homology 
regions flanking cluster of effector 
genes in PP2 (nleH, Cif*, espJ) of 
EPEC
This work 33, 34, 35, 36
pGE∆PP3 pGE derivative; with the homology 
regions flanking nleJ in PP3 of EPEC
This work 39, 40, 41, 42
pGE∆PP4 pGE derivative; with the homology 
regions flanking cluster of effec-
tor genes in PP4 (nleG, nleB, nleC, 
nleH*, nleD) of EPEC
This work 45, 46, 47, 48
pGE∆PP6 pGE derivative; with the homology 
regions flanking cluster of effector 
genes in PP6 (nleA/espL, nleH ,nleF, 
espO) of EPEC
This work 51, 52, 53, 54
MAT. AND MET. 60
pGE∆espZ-1 pGE derivative; with the homology 
regions flanking the espZ  gene of 
EPEC
This work 71, 74, 110, 111
pGE∆espZ-2) pGE derivative; with the homology 
regions flanking the espZ  gene and 
RBS 
This work 71, 72, 73, 74
pGE∆tir pGE derivative; with the homology 
regions flanking the tir  gene of 
EPEC
This work 77, 78, 79, 80
pGEminCD-
Amp.FRT
pGE derivative; with the homology 
regions flanking the minCD genes of 
E. coli K-12 and the bla gene (AmpR) 
flanked by two FRT sites inserted 
between homology regions 
Carlos 
Piñero, Thesis 
2014
pGE∆escN pGE derivative; with the homology 
regions flanking the escN gene of 
EPEC
This work 60, 61, 62, 63
pGE+map pGE∆map derivate; with map plus HR as in the chromosome This work 66, 67
pGE+espH pGE∆espH derivate;  with espH plus HR as in the chromosome This work 11, 68
pGE+espF pGE∆espF derivate;  with espF plus HR as in the chromosome This work 69, 70
pGE+espG pGE∆espG derivate;  with espG plus HR as in the chromosome This work 3, 6
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pGE∆PP4+nleC pGE∆PP4 derivate;  with the in-
tergenic region between nleG and 
nleB fused to nleC plus HR as in the chromosome
This work 83, 84, 85, 86
pGE∆lifA-like pGE∆IE2 derivative; with homology 
regions flanking lifA-like gene in IE2 
of EPEC
This work 87, 88
pGE∆nleE pGE derivative; with the homology 
regions flanking the nleE  gene in 
IE2 of EPEC
This work 90, 91, 92, 93
pGE∆eae pGE derivative; with the homology 
regions flanking the eae  gene of 
EPEC
This work 96, 97, 98, 99
pGETS∆grlR-
Amp.FRT
pGETS derivative; with AmpR 
(flanked by FRTs) between the ho-
mology regions flanking grlR regu-
lator gen of EPEC
This work 104, 105, 106, 107
pKD46 ( AmpR)  pSC101-ts ori, pBAD, Red 
recombinase expression plasmid.
(Datsen-ko and Wanner 
2000)pGE-espB∆mid pGE derivative; plus EPEC espB 
with deletion of amino acid 159-
218.
This work 112, 113, 114, 115
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Table 3. Oligonucleotides used in this workNumber Name Sequence (5´-3´)1 PF.CesF82 cgtgaaaagcgagggcgtcagtttg2 PR-tir.86  gcgccgtctgtttgtgaaggtagtg
3 F.XhoI.espG.
HR1(2)
ccggttCTCGAGgcctctggaatagttgcttgctttacactcag
4 R.espG.HR1.Fus tatgatgctataataaaactttattaatcaaaaccaata-
atagaaatc
5 F.espG.HR2.Fus taaagttttattatagcatcatatagtgtcaataatatacaa-
gatatttatagcgg
6 R.sphI.espG.
HR2(2)
cgacatGCATGCgaacaagggacaaatagctgaacaagta-
accgcg
7 F.check.∆espG cgattcatcggacagaatcatcagactttcat
8 R.check.∆espG tcggcgaaagaggatctgccatacatcaag
9 PF.escF.179 cgataaaagatctggtctcaaccatttctaacc10 PR.IE.espF gtaatacggaaatacattgag11 F.XhoI.espH.
HR1(3) 
cggCTCGAGccggaaggtgatgtgtcagttgatgatg12 PR.EspH.HR1.Fus cataaaataatactcctgattaatcacatacta
13 PF.EspH.HR2.Fus tgattaatcaggagtattattttatgctgttttctttttctcc
14 R.sphI.espH.HR2 gcccGCATGCctgacgccctcgcttttcacgataacg
15 F.XhoI.espG2.HR1 cccgCTCGAGtgaaggcgaaaaagatgattg
16 R.SacI.espG2.HR1.Fus cagatttaaacgtctgGAGCTCtacacatcctttttattc
17 F.SacI.espC.HR2.Fus gaataaaaaggatgtgtaGAGCTCcagacgtttaaatctggc
18 R.speI.espC.HR2 ccggACTAGTcagtagctgaagtaatggtattgc
19 F.check.∆IE5 cttaaccagataagagttaaatg20 R.check.∆IE5 gccacgggtaaaaagtggcgttttcg21 F.XhoI.espL.HR1 ccggCTCGAGgtgaagccaccctcctctcccctggcg22 R.SacI.espL.HR1 cagagattttaaGAGCTCaacaacatttgtgcctgaggaaag
23 F.SacI.lifA.HR2 cacaaatgttgttGAGCTcttaaaatctctgttaaagatg
24 R.SpeI.lifA.HR2 cctagACTAGTgtcagattctgaccagacg
25 F.check.∆IE6 gtcggtttttccgtcccaccgggatatc
26 R.check.∆IE6 gttaccaattcttgtctaatggc
27 F.XhoI.lifA-like.HR1 ccggCTCGAGggtgtgcaggatacctgcctctatcatc
28 R.SacI.lifA-like.HR1 cataccatctttatgGAGCTCtagttttgcacaatatattc
29 F.SacI.espL*.HR2 gtgcaaaactaGAGCTCcataaagatggtatgacc
30 R.SpeI.espL*.HR2 cctagACTAGTtcatgattgattagctaaccagg
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31 F.check.∆IE2 cagccagaaaaatgtggtgtttaac
32 R.check.∆IE2 ctgtttacctctttctcagggagtttag
33 F.XhoI.PP2.HR1.n cccCTCGAGagtgtgtggtaagaccgctg
34 R.PP2.HR1.n gaacgtgaaacgctGAGCTCccccattatccgagctag
35 F.PP2.HR2.n cggataatgggggagCTCAGCgtttcacgttcagc
36 R.sphI.PP2.HR2 cgcgGCATGCccgcctcctttcctccccggtctg
37 F.check.∆PP2 ctgaagtccggctggagtgagtg
38 R.check.∆PP2.n gggtaatcacgcaggtggtgatac
39 F.XhoI.nleJ.HR1 cccgCTCGAGgttgtaagtaccccgcttaggtg
40 R.SacI.nleJ.HR1.n ctactcctcataGAGCTCTtacgggtaaaagcattctttattc
41 F.SacI.nleJ.HR2.n gcttttacccgtaaGAGCTCtatgaggagtagcaaagtg-cactc
42 R.SphI.nleJ.HR2 cgcgGCATGCcatgcaccacctttatccag
43 F.check.∆nleJ gagacataaattcctaactgtg
44 R.check.∆nleJ ggtgaggtacaaccgcaaacac
45 F.XhoI.PP4.HR1.n gcgCTCGAGccgctgcaaatcctgcgtgc
46 R.SacI.PP4.HR1.n caagaaacacagGAGCTCatatgtgatactaaccg
47 F.SacI.PP4.HR2.n gtatcacatatGAGCTCctgtgtttcttgtgc
48 R.SphI.PP4.HR2.n cgcgGCATGCccggcagacttgctacctgc
49 F.check.∆PP4.n cattctggagtcagatgagaatgg
50 R.check.∆PP4 cagatatcgccctggttgatag
51 F.XhoI.PP6.HR1 cccgCTCGAGatttgtggatgacatttgttgtggacc
52 R.SacI.PP6.HR1.n cacactagatcGAGCTCgttggacaacggcatccaaatc
53 R.SacI.PP6.HR2.n ccgttgtccaacGAGCTCgatctagtgtgattacaatc
54 R.SphI.PP6.HR2.n cgcGCATGCccactttaactgcatgacagg
55 F.check.∆PP6 gccgatacagtgcgtggtgaggc
56 R.check.∆PP6.n ggtttacattgttctaccacaatag
57 F.SacI.HindIII.
Amp-FRT
cgcGAGCTCAAGCTTgaagttcctatactttctagaga-
ataggaacttcggaataggaacttcatgagtaaacttggtct-
gac
58 F.SacI.NdeI.Amp-FRT cgcGAGCTCCATATGgaagttcctatactttctagaga-ataggaacttcggaataggaacttcatgagtaaacttggtct-
gac
59 R.SacI.SpeI.Amp-FRT cgcGAGCTCACTAGTgaagttcctattcc-gaagttcctattctctagaaagtataggaacttctcggggaaat-
gtgcgcgg
60 F.XhoI.escN.HR1 ggccCTCGAGtgtgaaagagctgcagcgccagc
61 R.SacI.escN.HR1 gggcGAGCTCttaccgttcctaatactttaag
62 F.SacI.escN.HR2 gggcGAGCTCgtatgttggacagaattttatctattcg
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63 R.SphI.escN.HR2 gacatGCATGCgattccgttactacatttaattg
64 F.check.∆escN cggcgtacaagaaacgcgttatttg
65 R.check.∆escN cgaaaacatagtcttttttatg
66 F.XhoI.map.HR1 gcgCTCGAGagatctttgcaaaattgttcattc
67 R.SphI.map.HR2 gccGCATGCacacgttcctttatattactatg
68 R.SpeI.espH.HR2 gcgACTAGTctgacgccctcgcttttcacgataacg
69 F.XhoI.espF.HR1. ggccCTCGAGtaagcttcccaaatatgcgg
70 R.SphI.espF.HR2 cgccGCATGCcttcaggaaaaatataaccagataac
71 F.XhoI.espZ.HR1 ccggttCTCGAGacagtgcttgcatctgattagcttctttttctg
72 R.SacI.espZ.HR1.new.E gcgcGAGCTCcataaaaatagagaggtaatggatgcat-tatgc
73 F.SacI.espZ.HR2.new.E cgcgcGAGCTCctaatttagacatttacctgg
74 R.SphI.espZ.HR2 cgacatGCATGCgcgacaggcgcatcaacgtcgtaatcaac
75 F.check.∆espZ cctctttttccacactgagtgtcatatttcc
76 R.check.∆espZ gttaccgaaggagtaaataatgtcacccgc
77 F.XhoI.tir.HR1.new cgcgCTCGAGggggaaacttactgcgctgttattttttttc
78 R.SacI.tir.HR1.new gcgcGAGCTCacatatatccttttatttagaaatttg
79 F.SacI.tir.HR2.Fus aaggatatatgtGAGCTCatatatctgtgagtatttag
80 R.SphI.tir.HR2 cgcgGCATGCgtttgggctccaccacaatgag
81 F.check.∆tir ctacccagctactacaggccgtagc
82 R.check.∆tir caatcctaaaccagcactaagc
83 F.SacI.intergenic.nlGB GCGCgagctcaataaatattacccaagc
84 R.Fus.intergenic.nlGG ctatatcaaattcattcgtcgtcctgtttatcc
85 F.Fus.nleC gataaacaggacgacgaatgaatttgatatagtttattttg
86 R.SacI.nleC gcgcGAGCTCaaaatgtatgaatagtaac
87 F.SacI.lifA-like.HR2 ggccGAGCTCctgcaaaggtttagatattaac
88 R.SpeI.lifA-like.HR2 ggccACTAGTagaagctcagcaacttgtgtaagg
89 R.check.∆lifA-like gtgaaatgggagaaatctttagctac
90 F.XhoI.nleE.HR1 ggccCTCGAGctgcaaaggtttagatattaac
91 R.SacI.nleE.HR1 cagttcatggtaaGAGCTCagaagctcagcaacttgtg
92 F.SacI.HR2.nleE gctgagcttctGAGCTcttaccatgaactgc
93 R.SpeI.nleE.HR2 ggccACTAGTccctgccagtgagaggg
94 F.check.∆nleE catattccggatgttctttgatac
95 R.check.∆nleE gagcagatgtggatttcagcatg
96 F.XhoI.eae.HR1 ccggCTCGAGcgttatctgatgccaatgacg
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97 R.SacI.eae.HR1 gatatttattaaatGAGCTCgtttgggctccaccacaatgag
98 F.SacI.eae.HR2 gtggagcccaaacGAGCTCatttaataaatatctaatcattg
99 R.SpeI.eae.HR2 ggccACTAGTagatccttgccattataaatgc100 F.check.∆eae gcggaaaaaattggtgttg101 R.check.∆eae caatgaactggcatcag102 F.AscI.repA101 cttGGCGCGCCgttagtcttgatgcttcactg
103 R.I-SceI.XhoI.oriR101 cttGGCGCGCCgttagtcttgatgcttcactg
104 F.Xhol.HR1.grlR gcggCTCGAGttctactgcatttggtgtattaaag105 R.SacI.HR1.grlR ggccGAGCTCactaacctcactcctttcaatttg
106 F.SacI.RBS.HR2.
grlR ggccGAGCTCaactttaagaaggagatatatccatggaatc-taaaaataaaaatggcg
107 R.SphI.HR2.grlR ccggGCATGCctaactctcctttttccgcctc
108 F.check.∆grlR.n.2 gttagaggctaagatataac
109 R.check.∆grlR.n.2 gtgaagtgctcccaaagttg 110 R.HR1.espZ.Fus. ggagaaagatcatcatcgcatcgcataaaaatagagaggta-
atggatgc111 F.HR2.espZ.Fus gcgatgcgatgatgatctttctccttttgtctaatttagacatt-
tacctgg112 F.XhoI.HR1.espB.mid cccCTCGAGcagctgatgtctgattctgcg
113 R.HR1.espB.∆mid gcagtaaagcgactttcggaagccttcgccag
114 F.HR2.espB.∆mid cgaaggcttccgaaagtcgctttactgctgctgcc
115 R.sphI.HR2.
espB.∆mid
cgcGCATGCctccttctgtattgtgtacc
116 qPCR-lifAhomo Rev acgccgtgataaaatactccg
117 qPCR-lifAhomo For cgatacaacgcccttcattg
118 qPCR tir For cggaatagtctatcggctcatc
119 qPCR tir Rev tactttggataccttgccctg120 qPCR nleE2 For atggttgttgtgtacagaaatgac121 qPCR nleE2 Rev ctgcctttaaatctggtaactcataat
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3.1 Plasmid constructions 
3.1.1 Thermo sensitive plasmid for genome engineering (pGETS)
The pGETS is a KmR plasmid of 2817 bp with a thermo-sensitive pSC101-ori; it contains two I-SceI sites flanking a multiple cloning site (MCS) with the following 
restriction sites: XhoI, BsaI, SacI, NdeI, XbaI, HindIII, SpeI, AvrII and SphI. This 
plasmid was constructed ligating two DNA fragments: one encompassing the Km 
resistance cassette and the MCS (digested from the pGE) and the other with the 
repA101 and the pSC101-ori. The later fragment was amplified from the pKD46 thermo-sensitive plasmid. 
3.1.2 Design of pGE and pGETS derivate plasmids for EPEC genome engineering 
Derivative plasmids of pGE and pGETS harbor integrative cassettes for the deletion 
of genes sequences in the bacterial chromosome, and a backbone with a R6K or 
pSC101 origin of replication respectively. Two homology regions (HRs) flanking 
the gene to be deleted and cloned between XhoI and SphI or SpeI endonucleases 
compose the integrative cassette. When indicated, the constructions harbour a 
SacI site between the HRs. When positive selection of the deletion was needed, an 
AmpR cassette flanked by Flippase Recognition Target (FRT) sequences was cloned in the SacI site between the HRs, the Amp.FRT cassette was amplified from the pGEminCD-Amp.FRT (Piñero-Lambea C., PhD Thesis). The HRs were designed for 
the deletion of effector genes from the start codon to the stop codon (Figure 8).  In the case of deletion of espZ the plasmid pGE∆espZ was designed to delete espZ and 
its ribosome-binding site (RBS), leaving the next gene of the LEE2 operon (escI) 
with its own RBS. 
To insert genes in the bacterial chromosome, pGE plasmids were constructed with 
a DNA fragment encompassing the corresponding wild type orf of the effector and 
the flanking HRs. These cassettes for the insertion of espH, map, espF and espG 
were amplified from the chromosome with the external oligonucleotides used to 
amplified the HRs in the case of gene deletion. For the insertion of nleC a fusion 
PCR was done between the nleG and nleB intergenic region and the nleC gene. This fusion was cloned in the SacI site between the HRs of the respective pGE. To see details of the pGE plasmids for insertion see Table 2 and Table 3.
MAT. AND MET.67
4. Genome engineering of EPEC strains
EPEC mutant strains (Table 1) were generated using a markerless gene deletion 
or integration strategy, which is based in homologous recombination of suicide plasmids with I-SceI restriction sites and homology regions to the targeted gene, 
followed by the expression in vivo of the I-SceI endonuclease (Posfai, Kolisnychenko 
et al. 1999). Genome modifications, suicide plasmids and oligonucleotides used to 
screen the mutant strains are summarized in Table 4. 
Table 4. Modifications of the genome using pGE and pGETS plasmids
Strain to be modified
Plasmid to be 
integrated Resulting Strain
Checking 
primers
EPEC pGE∆escN EPEC∆escN 64, 65
EPEC pGE∆map EPEC∆map 1, 2
EPEC∆map pGE∆espG EPEC∆map.espG 7, 8
EPEC∆map.espG pGE∆espF EPEC∆map.espGF 9, 10
EPEC∆map.espGF pGE∆espH EPEC9 11, 14
EPEC9 pGE∆IE5 EPEC8 19, 20
EPEC8 pGE∆IE6 EPEC7 25, 26
EPEC7 pGE∆IE2 EPEC6 31, 32
EPEC6
PGE∆PP2-Amp.FRT EPEC5-Amp.FRT 37, 38
SacI
SacI
HR1 HR2 KmR
I-SceI I-SceI
XhoI SphI/SpeI
HR1 HR2 KmR pSC101
I-SceI I-SceI
XhoI SphI/SpeI
R6K
HR1 HR2 KmR
I-SceI I-SceI
XhoI SphI/SpeI
R6Keffector
Integrative cassete backbone
pGE
pGETS
pGE+effector
Figure 8. Plasmid for gene(s) deletion and gene integration linear 
maps are displayed. pGE and pGETS plasmid vectors for E.coli genome 
engineering, with an integrative cassette with the mutant allele. pGE contains 
a suicide origin of replication R6K (pir dependent). And pGETS contains 
a thermo-sensitive origin of replication pSC101. Plasmids pGE+effector 
carry the corresponding effector gene with HRs for gene integration.
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EPEC5-Amp.FRT PGE∆PP2 EPEC5 37, 38
EPEC5
pGE∆PP3-Amp.FRT EPEC4-Amp.FRT 43, 44
EPEC4-Amp.FRT pGE∆PP3 EPEC4 43, 44
EPEC4
pGE∆PP4-Amp.FRT EPEC3-Amp.FRT 49, 50
EPEC3-Amp.FRT pGE∆PP4 EPEC3 49, 50
EPEC3
pGETS∆PP6-
Amp.FRT
EPEC2-Amp.FRT 55, 56
EPEC2-Amp.FRT pGE∆PP6 EPEC2 55, 56
EPEC2 pGE∆espZ EPEC1 75, 76
EPEC1 pGE∆tir EPEC0
EPEC7 pGE∆lifA-like EPEC7∆lifA-like 31, 89
EPEC7
pGE∆nleE EPEC7∆nleE 94, 95
EPEC2 pGE+map EPEC2+map 1, 2
EPEC1 pGE+map EPEC1+map 1, 2
EPEC0 pGE+map EPEC0+map 1, 82
EPEC2 pGE+nleC EPEC2+nleC 49,  50
EPEC1 pGE+nleC EPEC1+nleC 49,50
EPEC0 pGE+nleC EPEC0+nleC 49, 50
EPEC2 pGE+espH EPEC2+espH 11, 14
EPEC1 pGE+espH EPEC1+espH 11, 14
EPEC0 pGE+espH EPEC0+espH 11, 14
EPEC2+map pGE+espH EPEC2+map+espH 11, 14
EPEC2+map+espH pGE+espF EPEC2+map+espH+espF 9, 10
EPEC2+map+espH+espF pGE+espG EPEC2-LEE+ 7, 8
EPEC2 pGE∆eae EPEC2∆eae 100, 101
EPEC1 pGE∆eae EPEC1∆eae 100, 101
EPEC pGE∆grlR EPEC∆grlR 108, 109
EPEC pGE∆espZ(1) EPEC∆espZ(1) 75, 76
EPEC pGE∆espZ(2) EPEC∆espZ(2) 75, 76
EPEC2 pGE-espB∆mid EPEC2∆mid 112, 115
EPEC1 pGE-espB∆mid EPEC1∆mid 112, 115
4.1 Use of suicide pGE plasmids with R6K origin of replication
The EPEC strain to be modified was initially transformed with a plasmid pACBSR 
(SpR or CmR) (Herring, Glasner et al. 2003), expressing the I-SceI and λ Red 
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proteins under the control of the PBAD promoter (inducible with L-arabinose), 
and subsequently electroporated with the corresponding pGE-based suicide vector 
(KmR). Colonies that grew in LB-Km-Cm (or Sp) plates had integrated the suicide 
plasmid in their genome (cointegrants) by recombination. Correct integration 
was verified by PCR. The colonies were grown for 6 h in LB-Cm (or Sp) liquid 
medium containing L-arabinose 0.4% (w/v) with agitation (180 rpm) to induce 
the expression of I-SceI and to cause a double-strand break in the genome that 
promotes a second step of recombination. A sample of these cultures was streaked 
on LB-Cm (or Sp) agar plates and incubated o/n to isolate individual colonies, 
which were replicated in LB-Cm/Sp and LB-Km-Cm/Sp agar plates to identify 
Km-sensitive colonies. The resolution of the cointegrates can either revert the 
sequence to the WT or maintain the mutant allele sequence, depending on the site 
of the crossover. Using specific primers (Table 4), the mutants harboring deletion 
or insertion of genes were identified by PCR.
Deletion of the cluster of genes present in EPEC prophages (PPs) required a positive 
selection to select the mutant strains.  In these cases, pGE-Amp.FRT vectors were 
initially used to carry out the deletion of cluster of genes present in PP2, PP3 and PP4, 
followed by a second mutation step with the corresponding pGE-deletion vector to 
remove the Amp.FRT cassette.  After electroporation of EPEC strains having pACBR 
plasmid with the corresponding pGE-Amp.FRT, the cointegrants were plated in LB-
Amp-Km-Cm (or Sp). Individual colonies were grown for 6 h in LB-Amp-Cm (or 
Sp) liquid medium containing L-arabinose 0.4% (w/v) with agitation (180 rpm), to 
induce the double-strand brake and the second recombination. A sample of these 
cultures was streaked on LB-Amp-Cm (or Sp) agar plates and incubated o/n to 
isolate individual colonies, which were replicated in LB-Amp-Cm (or Sp) and LB-
Amp-Km-Cm (or Sp) agar plates to identify AmpR and KmS colonies. Deletions of 
genes were identified by PCR (Table 4). The Amp-FRT resistance cassette was later 
removed as explained in section 4.3.  
4.2 Use of suicide pGETS plasmids with thermo-sensitive pSC101 origin of 
replication
EPEC strains harbouring pACBSR-CmR were transformed with the pGETS-KmR 
vector designed for gene deletion, which contains the thermosensitive origin of 
replication pSC101. The transformants were plated in LB-Km-Cm and incubated 
o/n at 30°C to obtain individual colonies. Several colonies were restreaked in LB-
Km-Cm plates and incubated at 42°C during 7-9 h (to induce plasmid integration), 
and the plates were kept for additional 12-24 h at 37°C. Between the small and large 
colonies grown on the plates, the larger colonies were selected and restreaked in 
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LB-Km-Cm plates and incubated o/n at 37°C. The colonies were grown for 6 h in LB-
Cm liquid medium containing L-arabinose 0.4% (w/v) with agitation (180 rpm) to 
induce the expression of I-SceI and to cause a double-strand break in the genome to 
promote a second step of recombination. A sample of these cultures was streaked 
on LB-Cm agar plates and incubated o/n to isolate individual colonies, which were 
replicated in LB-Cm and LB-Km-Cm agar plates to identify KmS colonies. Using 
specific primers (Table 4), the mutants harboring deletion or insertion of genes 
were identified by PCR screening. 
The pGETS can also be integrated by a single step of recombination; EPEC3 mutant 
harbouring pACBSR-SpR was transformed with pGETS∆PP6-Amp.FRT and the 
transformants were plated and incubated o/n at 30 oC. Individual colonies were 
grown at 30 oC in liquid LB medium with agitation (180 rpm) until the cultures 
reached an OD
600
 of 0.5. Then, L-arabinose 0.4% (w/v) was added to induce the 
expression of I-SceI and the λ Red proteins, which triggered the excision from 
the vector on the integrative cassette as lineal DNA, protect it from digestion and assisted in the posterior double recombination event. The temperature was shifted 
to 37 oC to avoid replication of pGETS plasmid. The cultures were further grown 
during 4 h and streaked LB-Amp-Sp to select the mutant strains that had deleted 
the cluster of genes present in PP6 and also to maintain the selection of the pACBSR 
plasmid. The grown colonies were analyzed by PCR with specific oligonucleotides 
to check the correct deletion, Amp.FRT resistance cassette was later removed. 
4.3 Removal of the Amp.FRT cassette
After deletion of the clusters of effector genes localized in EPEC PPs using positive 
selection with Amp.FRT cassette, we deleted the Amp.FRT cassette of the resulting 
strains. Expression of flippase recombinase from the pCP20 is the conventionally 
method to remove the Amp.FRT cassette from bacterial chromosomes but leaves 
the FRT site as a “scar” in the chromosome. In addition, transformation of pCP20 
is not stable in EPEC for unknown reasons. Hence, excision of the Amp.FRT strains 
was done using the homologous recombination strategy that leaves no FRT scars 
in the chromosome. The EPEC mutants with the Amp.FRT cassette and pACBSR-
SpR (or CmR) were transformed with their respective pGE deletion plasmid 
lacking the Amp.FRT cassette.  The transformants were plate in LB Amp-Km-Sp 
(or Cm) and were incubated at 37 oC o/n. Colonies that grew in LB-Amp-Km-Sp 
(or Cm) are the cointegrants and had two copies of the mutant allele with and 
without the Amp.FRT cassette respectively. Correct integration was verified by 
PCR. The colonies were grown for 6 h in LB-Cm (or Sp) liquid medium containing 
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L-arabinose 0.4% (w/v) with agitation (180 rpm) to induce the expression of I-SceI and to cause the double-strand break in the genome and promote the second 
step of recombination between the two mutant alleles. A sample of these cultures 
was streaked on LB-Cm (or Sp) agar plates and incubated o/n to isolate individual 
colonies, which were replicated in LB-Cm (or Sp) and LB-Amp-Cm (or Sp) agar 
plates to identify Amp-sensitive colonies, which were the EPEC mutant strains 
without the Amp.FRT cassette. Amp-sensitive mutant were screened by PCR using 
specific oligonucleotides listed in Table 4.
Plasmid pACBSR was cured from the final strains by growth in liquid LB (5 passages 
approximately) and streaking on LB agar plates. Individual colonies were replicated 
in LB and LB-Cm (or Sp) plates to screen for Cm (or Sp)-sensitive colonies. 
5. SDS-PAGE and Western blot
Sodium Dodecyl Sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blot were performed following standard methods (Ausubel F.M. 2002) 
using the Miniprotean III system (Bio-Rad). Proteins separated by SDS-PAGE were 
either subjected to Coomassie Blue R-250 (Bio-Rad) staining or Western blot. For 
the latter, the proteins were transferred to a polyvinylidene difluoride membrane 
(PVDF, Immobilon-P, Millipore) using semi-dry and wet electrophoresis (Bio-Rad), 
as previously described (Ausubel F.M. 2002). Antibodies employed for Western blot are described in Table 5. Membranes were developed by chemiluminiscence using 
the Clarity Western ECL Substrate kit (Bio-Rad), SuperSignal West Femto (Thermo 
Scientific) or a mixture of 100 mM Tris-HCl (pH 8.0) containing 1.25 mM luminol 
(Sigma), 0.22 mM cumaric acid (Sigma), and 0.0075% (v/v) H2O2 (Sigma). The 
membranes were then developed by exposure to X-ray films (Agfa) or with a Fuji 
LAS 3000 image when the signal was quantified. 
For the analysis of the secretion of T3SS components, EPEC strains were grown 
in DMEM and bacteria were harvested from 1 ml aliquots of the induced cultures 
by centrifugation (14000 g, 5 min). To obtain whole-cell protein extracts, the cells 
were resuspended in 400 µl of phosphate-buffered saline (PBS), mixed with 100 
µl of 5X SDS-PAGE sample buffer and boiled for 10 min, and then protein were 
separated by SDS-PAGE and analyzed by Western blot. For the analysis of the T3-
secreted proteins, the bacterial cultures were centrifuged at 4 oC in 50 ml Falcon 
tubes (BD Biosciences) during 5 min (4000 rpm). This was done twice to ensure 
removal of most bacterial cells. Later 1 ml of the culture supernatants was chilled 
on ice and incubated 60 min with trichloroacetic acid (TCA 20% w/v; Merck) for 
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precipitation. After cold centrifugation (14000g, 15 min), TCA-precipitated protein pellets were rinsed with cold acetone (-20 oC) and resuspended in 30 µl of SDS-
PAGE sample buffer for Coomassie staining or Silver staining. 
To evaluate the amount p65 protein into HeLa cells after infection with EPEC 
strains. HeLa cells were scraped from the wells using 500 μl of lysis buffer 1X. 
To prepare 7 ml of lysis buffer 1X we mixed: 175 μl of Tetrasodium Diphosphate 
Decahydrate-NaPPi 250mM, 25 μl of Protease Inhibitor Cocktail (P8340, Sigma), 1 
ml of lysis buffer 7X and 5.66 ml of H2O. The lysis buffer 7X is: Tris base 350mM 
(pH 7.4), NaCl 1.05 M, EDTA 14 mM, and NP-40 7%. This buffer was kept in aliquots of 1 ml at -20 oC until use. The lysed cell samples were recovered in a 1.5 ml 
eppendorf tube and incubated during 30 min at 4 oC with rotation.  Then samples 
were centrifuged (14000g, 15 min) and 400 μl of the supernatant were mixed with 
5X SDS-PAGE sample buffer and then protein were separated by SDS-PAGE and 
analyzed by Western blot.
Table 5. Antibodies used for Western BlotsProtein Primary Antibody Secondary AntibodyEspB Rabbit polyclonal anti-EspB 
(1:2000)
Protein A-HRP (Life Technologies, 
1:5000)
EscC Rabbit polyclonal anti-EscC 
(1:1000)
Protein A-HRP (Life Technologies, 
1:5000) 
EscJ Rabbit polyclonal anti-EscJ 
(1:5000)
Protein A-HRP (Life Technologies, 
1:5000)EscD Rabbit polyclonal anti-EscD 
(1:1000)
Protein A-HRP (Life Technologies, 
1:5000) 
GroEL anti-GroEL mAb-POD (Sig-
ma, 1:5000)Tir Mouse monoclonal anti-Tir 
(1:1000)
Goat anti-mouse HRP conju-
gated (Jackson ImmunoResearch, 
1:5000)
NF-κB p-65 Rabbit polyclonal anti NFκB 
p-65 SC-109 (Santa Cruz, 
1:1000)
Goat anti-rabbit HRP conju-
gated (Jackson ImmunoResearch, 
1:5000)Tubulin Mouse monoclonal anti-
alpha Tubulin clone DM1A 
(Sigma, 1:1000)
Goat anti-mouse HRP conju-
gated (Jackson ImmunoResearch, 
1:10000)Intimin Rabbit polyclonal anti-inti-
min-280 (1:5000)
Protein A-HRP (Life Technologies, 
1:5000)
MAT. AND MET.73
6. Mammalian cell cultures in vitro
The human cell lines HeLa (ATCC, CCL-2) were routinely grown as monolayers in 
DMEM, supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma) 
and 2 mM glutamine, at 37 oC with 5% CO2. During experiments of infections to 
evaluate individual injection of NleC and Tir by the EPEC-strains, the HeLa cells 
were grown in DMEM supplemented with 10% fetal bovine serum (FBS; Sigma), 
2 mM glutamine and 1% of MEM non-essential amino acid solution 100X (Sigma). 
Swiss 3T3 mouse fibroblasts (ATCC; CCL-92) were grown as monolayer in DMEM-
high glucose, with 4500 mg glucose/l (D5671; Sigma) supplemented with 10% of 
heat-inactivated fetal calf serum (FCS; Sigma), 2 mM glutamine and 1X of MEM 
non-essential amino acid solution 100X (Sigma).
6.1 EPEC infections of mammalian cells cultured in vitro
HeLa cells were seeded approximately 24 h before to the infection to obtain ~90% 
cell confluency i.e., 1.8 - 2.0 x 105 cells per well in 24-well tissue culture plates 
(Falcon). HeLa cells were washed once with pre-heated serum-free DMEM 2 h 
before the infection with EPEC strains. Multiplicity of infection (MOI) and time of 
infection are described in individual experiments. 
During infections to evaluate individual translocation of NleC and infections to 
evaluate the translocation of Tir by EPEC-strains, 2.4 x 105 HeLa cells/well were 
seeded 48 h before to the infection to obtain cell confluency between 70% - 80% 
(8.4 and 9.6 x 105 cells) in 6-well tissue culture plates (Falcon). HeLa cells were 
washed three times with sterile pre-warmed PBS (Sigma) and serum-free DMEM was added to starve the cells 2 h previous to the infection. Infections were done 
with 1.5 ml of EPEC strains and 3 ml of EPEC0 strains cultures, induced during 3 h 
previous to the infection. Cells were infected 1 h and then washed three times with 
PBS and incubated for additional 3 h with 200 μg/ml of gentamicin in DMEM. Cells 
were washed with PBS to remove the unbound bacteria and the cell extracts were 
analyzed by Western blot. At the beginning of the infection plates were centrifuged 
to synchronize the infection (500 g, 5 min). 
To analyze the phenotype of filopodia formation, infection with EPEC strain was 
done in Swiss 3T3 cells because these cells have more active actin dynamic than 
other cell lines. The Swiss 3T3 cells were seeded 48 h before to the infection to 
obtain cell confluence between 60% and 70% (1.2 and 1.4 x 105) cells in 24 well 
tissue culture plates (Falcon). Swiss 3T3 cells were washed three times with sterile 
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pre-warmed PBS (Sigma) and serum-free DMEM was added to starve the cells 2 h 
previous to the infection. Infections were done with 500 μl of EPEC strains induced 
during 3 h previous to the infection. The plates were centrifuged to synchronize 
the infection (500 g, 5 min) and the infection was incubated during additional 5 min.
6.2 β-Lactamase translocation assay
The previously described assay to quantify β-lactamase (Bla) translocation was 
adapted for EPEC-wt and EPEC derived mutant strains (Charpentier and Oswald 
2004). HeLa cells were seeded in a 96-well opaque plate (Nunc) 48 h previous 
to the infection to obtain a cell confluence of 4x104 cell/well, at 37oC with 5% 
CO2. The culture medium of the cells was changed 2 h before to the infection by 
serum-free DMEM. HeLa cells were infected with the induced EPEC strains with a 
MOI 100:1, after 30 min of infection 1 mM of IPTG was added, and the infections 
were maintained during 1 extra hour under these conditions. Then cells were 
washed twice with preheated DMEM and cover with 100 µl of HBSS and 20 µl of 6X 
CCF2/AM solution (CCF2/AM final concentration 1 µM, Invitrogen). Samples were 
incubated for 1 h in the dark at a room temperature (RT) and plates were read in 
a SpectraMax M2 fluorometer (Molecular Devices) with a filter set 450/520 nm.
6.3 LDH-release assay 
HeLa cells were seeded in 24 well plates and washed twice with preheated color-
free (without phenol-red) DMEM (Sigma) 2 h previous to the infection. HeLa cells 
were infected with EPEC induced strains using a MOI 200:1 during 1.5 h and then 
cells were washed twice with DMEM color-free and incubated with DMEM color-
free during additional 1.5 h. Plates were centrifuged (250 g, 10 min) and 500 µl 
of supernatants were harvested and maintained in 1.5 ml eppendorf tubes at 4oC. 
To obtain the total LDH release from the cells, uninfected cells were treated with 
Triton X-100 (1%, 10 min). LDH release was measured mixing 100 µl of the culture 
supernatants and 100 µl of the reaction mixture of the LDH Cytotoxicity Detection 
Kit (Clontech). The percentage of LDH release is calculated as the amount measured 
in the supernatant divided by the total amount of LDH in the cells. Absorbances of 
samples were read at 490 nm using iMark ELISA plate reader (Bio-Rad).
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6.4 Immunofluorescence microscopy
Infected HeLa cell cultures, grown on coverslips in 24-well plates, were washed three 
times with 1 ml/well of PBS (sigma), fixed with 4% (w/v) paraformaldehyde (in 
PBS, 20 min, RT) and washed again with PBS three times. Cells were permeabilized 
by incubation in a solution of 0.1% (v/v) of saponin (Sigma) in PBS for 10 min 
and washed with PBS three times. The primary antibodies were added in PBS-
10% goat serum (Sigma) and incubated 60 min at RT. Coverslips were washed 
three times with PBS. Then coverslips were incubated 45 min with the conjugated 
secondary antibodies in PBS-10% goat serum, together with Phalloidin TRITC 
(1:500; Sigma) and DAPI (1:1000; Sigma) to label F-actin and DNA, respectively. 
Coverslips were washed 3 times with PBS after incubation and 4 μl of ProLong 
Gold anti-fade reagent (Life technologies) was used to mount coverslips and they 
were dried o/n. Samples were observed in a SP5 confocal microscope (Leica) using 
the 100X objective or a fluorescence Olympus microscope (BX61) using the 40X 
and 60X objective. Reagents, antibodies and fluorophores used in microscopy is described in Table 6.
Infected Swiss 3T3 cell cultures, grown on coverslips in 24-well plates, were washed 
three times with 1 ml/well of PBS (sigma), fixed with 4% (w/v) paraformaldehyde 
(in PBS, 20 min, RT) and washed again with PBS three times. Fixed monolayers were 
treated with 50 mM NH4Cl (10 min, RT) for formaldehyde function neutralization. 
Cells were permeabilized by incubation in a solution of 0.2% (v/v) of Triton X-100 
in PBS (4 min, RT) and washed with PBS two times. Then cell were treated with PBS-
0.2% BSA (10 min, RT). The primary antibodies were added in PBS-0.2% BSA and 
incubated 60 min at RT. Coverslips were washed twice with PBS and then treated 
with PBS-0.2% BSA during 5 min. Then coverslips were incubated 45 min with 
the conjugated secondary antibodies in PBS-0.2% BSA together with Oregon-green 
Phaloidine (1:100, Invitrogen) to label bacteria and actin respectively. Coverslips 
were washed 3 times with PBS after incubation and were mounted with one drop 
of prolong reagent and were dried o/n. They were then observed at the Zeiss Axio 
imager microscope. The projections of the images were done with AxioVision LE 
re. Software (Zeiss). The list of antibodies used is described in Table 6.
After inducing EPEC strains in serum-free DMEM during 2.5 h, bacteria was collect-
ed and washed with PBS and resuspended to a 0.5 OD
600
 and keep on ice. Coverslips 
were treated previously with 50 μl of poly-L-Lysine solution (ChemCruz) at RT, 
after 30 min the poly-L-Lysine was removed. Then 10 μl of the cell solution were 
added over the coverslips and incubated during 30 min at RT until it is dry, use the 
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chamber. Coverslips were washed with PBS to remove unbound bacteria. Add 300 
μl PFA 4% during 20 min. Coverslips were washed 3 times with PBS and later the 
bacteria were stained with antibodies anti intimin-280 (Table 6).
Table 6. Reagents and antibodies used for fluorescence microscopy
Antigen Primary reagent/antibody Secondary antibody
EPEC
Rabbit polyclonal anti-intimin-280 
(1:500)
Rabbit polyclonal anti O127 (1:100)
Goat anti-rabbit-AL-
EXA488 (Life technolo-
gies, 1:500)Donkey anti-rabbit-AL-
EXA488 (Jackson Immu-noResearch, 1:100)
Actin
Phalloidin-TRITC (1:500)
Oregon-green Phalloidin (1:500)
DNA
DAPI (4’,6-diamidino-2-phenilindole, 
1:1000, Life technologies)
Vinculin 
Monoclonal mouse anti-Vinculin 
clone hVIN-1 (1:400, Sigma)
Goat anti-mouse-AL-
EXA488 (Life technolo-
gies, 1:500)
7. EPEC infections of human intestinal biopsies cultured in vitro
Duodenal mucosal biopsies taken with informed consent and ethical approval were 
maintained in organ culture and infected for 8 h with o/n LB cultures of EPEC-wt 
and EPEC mutant strains, as described previously in (Knutton, Lloyd et al. 1987) . 
7.1 Samples for Scanning Electron Microscope (SEM)
Infected intestinal biopsies were thoroughly washed and fixed with 3% of 
glutaraldehyde and processed for scanning electron microscopy (SEM) (Knutton 
1995) and examined in a scanning electron microscope Jeol JSM-6390. 
8. RT-PCR to evaluate efa1/lifA-like and nleE2 gene expression
RNA was extracted from the EPEC strains and reversed transcribed by RT-PCR 
as described in(Hemrajani, Marches et al. 2008, Pallett, Berger et al. 2014). The 
primers used for the RT-PCR are listed in Table 3.
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1. Markerless gene deletion strategy in EPEC O127:H6 E2348/69
We decided to use in our research the prototype EPEC O127:H6 strain E2348/69 which has been widely studied to characterize the effectors of the T3SS using conventional genetics, genomic and proteomic analysis, providing a good knowledge of the whole repertoire of effectors encoded in this EPEC strain (Kenny, DeVinney et al. 1997, Iguchi, Thomson et al. 2009, Deng, Yu et al. 2012). We wanted to use a strategy for deletion and integration of genes in EPEC genome without leaving any marker or “scars” in the chromosome. The marker-less gene replacement strategy chosen is based in the homologous recombination of a mutant allele, cloned in a 
suicide plasmid, and flanked by the restriction sites for the meganuclease I-SceI (Figure 9). 
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Figure 9. Markerless gene deletion strategy. Deletions were carried out with suicide plasmids pGEs with mutant alleles. pGE contains an R6K replication origin 
(π protein dependent) and pGEts contains a thermo-sensitive replication origin ori101 (replicates at 30oC and can not replicate 37-42oC). The lacks of π protein in EPEC or the growth at non-permissive temperature induce integration of pGEs and co-integrants of the wt and mutant alleles are obtained. Co-integrants are 
identified by the Km resistance. Expression of the I-SceI in vivo from a helper plasmid induces a double strand brake (DSB) and after a second homologous recombination, the chromosome can revert to the wt or to the mutant allele.
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Following the expression in vivo of I-SceI, which induces cleavage of the I-SceI sites generating double-strand break (DSB) in the chromosome of the co-integrant strain that stimulates a repair mechanism driven by a second homologous recombination resulting in either mutant or wt allele being maintained in the chromosome (Posfai, 
Kolisnychenko et al. 1999). Genome modifications were done with this marker-
less gene replacement strategy with minor modifications, like the expression of λ Red proteins to assist recombination (Pinero-Lambea, Bodelon et al. 2014). 
1.1 Deletion of the ATPase escN and the negative regulator grlR
With the aim to evaluate the applicability in EPEC of the marker-less gene deletion strategy, we tested the deletion of escN, which is the ATPase that energizes the protein secretion through the T3SS injectisome. We generated a suicide plasmid, 
pGE∆escN, with a mutant allele for deletion of escN. After integration of this plasmid and resolution of the co-integrants we selected the strain that resolved to the mutant 
∆escN allele.  To appraise the behavior of EPEC∆escN we evaluated the pattern of 
proteins secreted into the extracellular medium compare to EPECwt strain (Figure 10). In EPEC, the LEE genes are expressed at 37 oC in DMEM and repressed in LB medium (Kenny, Abe et al. 1997). After growth of EPECwt in DMEM, we could 
observe the EspA, EspB and EspD translocators in the extracellular medium. We could also observed EspC autotransporter, which is secreted independently of the 
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Figure 10. Proteins secreted by EPEC. (A) Schematic representation of the T3SS 
injectisome, indicating the filament of EspA, the translocator proteins EspB and EspD, and the ATPase EscN. Secretion of the autotransporter EspC is also shown. 
(B) Coomassie staining of the proteins in the extracellular media of EPECΔescN and EPEC-wt strains grown 4h at 37oC in DMEM or LB. The translocators EspABD and the autotransporter EspC proteins are labeled. Molecular standards mass proteins are shown in kDa.
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T3SS.  In contrast, EPEC∆escN bacteria, grown under the same conditions, do not 
secrete the translocator proteins to the extracellular medium, while EspC is still found because the disruption of the T3SS does not affect its secretion. 
Next, we tested the marker-less deletion of grlR, which encodes a negative regulator of Ler and indirectly of LEE genes since Ler is a positive regulator of all other LEE promoters and of EspC, which is located outside the LEE (Kaper, Nataro et al. 2004). It has been reported that deletion of grlR in EPEC derepress LEE island 
and induces its expression in LB (Garcia-Angulo, Martinez-Santos et al. 2012). We generated the deletion of the grlR in EPECwt strain and compared the pattern of 
the extracellular proteins between the two strains grown in LB. Contrary to the 
parental WT strain, EPECΔgrlR strain was able to secrete the translocator proteins 
EspABD and the autotransporter EspC to the extracellular medium even under the repressing conditions in LB  (Figure 11). 
2. Generation of the effector mutant EPEC strains
Once we confirmed that the marker-less gene deletion strategy was useful to manipulate EPEC genome, we designed a set of suicide plasmids with R6K- or pSC101-thermosensitive origin of replication for the deletion of all effectors genes known in the genome of EPEC strain E2348/69. The strategy was done to delete the effector genes from the start to the stop codon of individual ORFs of gene effectors or 
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Figure 11. Secreted proteins in LB by EPECwt and EPECΔgrlR. Coomassie 
staining of the proteins found in the extracellular media of cultures of EPECwt 
and EPECΔgrlR grown in LB at 37 oC. The translocators EspABD and the autotransporter EspC are labelled. Molecular mass standards are shown in kDa.
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clusters of gene effectors, maintaining the endogenous transcriptional promoters and terminator signals of these genes and leaving no antibiotic resistance markers or scars in the chromosome. 
2.1 Deletion of LEE encoded effector genes except espZ and tir
We started with the deletions of LEE encoded effector genes (Figure 12). Since all the genes responsible for the assembly of the T3SS injectisome are localized in the 
LEE island, we wanted to confirm that these deletions do not affect T3SS.  We made the sequential deletion of the following effector genes: map, espG, espF and espH. We decided not to delete espZ and tir at this stage. In the case of espZ it was due for its reported ability to control the effector translocation through the T3SS (Berger, Crepin et al. 2012), which may be necessary to provide a physiological amount of translocation of the remaining effectors proteins. In the case of Tir its translocation and insertion into the enterocyte plasma membrane and its interaction with intimin to trigger actin polymerization beneath the adherent bacterium could be useful to evaluate the functionality of the T3SS injectisome (Kenny, DeVinney et al. 1997). After deletion of map, espG, espF and espH we obtained the strain called EPEC9 Table 1. 
2.2 Deletion of non-LEE encoded effector genes
Next we initiated the deletion of the non-LEE effector genes. Since these effector genes are in clusters in integrative elements (IEs) and prophages (PPs) in the genome of EPEC Figure 13, the HR were selected to flank these clusters in order to delete simultaneously several effector genes. The order of deletion followed was: IE5 (espG and espC), IE6 (espL, nleB1, nleE1, efa1/lifA) and IE2 (espL*, nleB*, 
LEE
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Figure 12. LEE effector genes. Representation of the LEE island. Effector genes are labeled in red. The order of deletion is numbered: deletion 1, 2, 3, 4 are for map, espG, espF and espH respectively. The espZ and tir genes were not deleted at this stage given their role in regulating T3SS translocation and actin-pedestal formation. Scale of 5kb is indicated at the bottom.
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nleE2, efa1/lifA-like). The resulting strain was called EPEC6. Although EspC is not an effector protein, we deleted espC together with espG in the IE5. EspC is an autotransporter protein, which was reported to cause cytopathic effect on epithelial cells and to be internalized in the host cell in a T3SS-dependent manner (Vidal 
and Navarro-Garcia 2006, Vidal and Navarro-Garcia 2008). EspC cytotoxicity is characterized by cell rounding and cell detachment phenotypes, which are induced by cytoskeletal and focal adhesion disruption and depends on its internalization and functional serine protease motif (Navarro-Garcia, Canizalez-Roman et al. 2004, Navarro-Garcia, Serapio-Palacios et al. 2014) .Additionally, it has been reported that EspC is involved in EPEC-mediated cell death and induces apoptosis and necrosis (Serapio-Palacios and Navarro-Garcia 2016). Lastly, we deleted the effector genes present in PPs following this order: PP2 (nleH1, cif, espJ), PP3 (nleJ), PP4 (nleG, nleB, nleC, nleH, nleD) and PP6 (nleA/espI, nleH2, nleF, espO). After these 
deletions we obtained the strain called EPEC2. As explained later the functionality of the T3SS was evaluated after every deletion.  
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Figure 13. Non-LEE effector genes in the chromosome of EPEC E2348/69. Effector genes located outside the LEE are localized in integrative elements (IE) and prophages (PP). Effector genes are labeled in red. The red bars indicate the cluster 
of genes deleted. Pseudogenes are specified with asterisk. The order of deletion is numbered. Scale of 5 kb is indicated at the bottom.
RESULTS 84
2.3 Deletion of espZ and tir
We then focused on the deletion of espZ and tir. Considering that espZ was the first gene of the LEE2 operon, it was possible that its deletion could affect the expression of downstream genes in the operon and, as a consequence, of the T3SS injectisome. 
We first deleted the ORF of espZ in an EPECwt strain, from the start codon to the stop codon, generating a mutant strain with escI as the first gene of the LEE2 operon. In this mutant, upstream of escI is localized its own RBS and the RBS of espZ (Figure 14A). We observed reduction in the secretion of the translocator proteins EspABD in this EPECΔespZ-1 mutant strain (Figure 14B). Thus, we designed a different plasmid for deletion of espZ and its RBS. With this new construct the LEE2 starts with escI and its RBS (Figure 14A) and the mutant EPEC∆espZ-2 has a level of T3SS secretion similar to the EPECwt strain (Figure 14B). Thus, we used this second construction to delete espZ in the EPEC2 strain, generating EPEC1, which only carries tir effector. Next we deleted tir generating and EPEC0 strain devoid of all known T3 secreted effector genes, see all the generated strains in Table 1. 
2.4 Confirmation of gene deletion and genome sequencing
During generation of each mutant strain we tested by PCR the parental and 
mutant strains to confirm introduction of the expected deletion (see Table 4 for 
primers used). After all deletions, we performed a PCR to confirm all deletions in EPEC0 strain. In Figure 15 we show the final confirmation of all deletion in EPEC0 compared to EPECwt. 
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Figure 14. Extracellular proteins secreted by EPECwt and ΔespZ mutants. (A) Schematic representation of gene organization of espZ and escI with their RBS in the 
LEE2 operon of wt strain and ΔespZ-1 and ΔespZ-2 mutants. (B) Coomassie staining of 
proteins secreted in the extracellular media of EPECΔescN, EPECwt, EPECΔespZ-1 and 
EPECΔespZ-2 strains grown 4 h in DMEM at 37 oC. The translocators EspABD and the autotransporter EspC are labeled. Molecular standards mass proteins are shown in kDa.
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We also performed whole genome sequencing of the parental EPECwt strain and the EPEC1 strain, which maintains Tir translocation into HeLa cells (see 
below). Comparison of these genomes confirmed that the only differences between them were the designed deletions of effector genes (Table 7). 
Table 7. Positions of genome deletions respect to EPECwtEffector(s) deleted in EPEC1 Deletions Size of deletionStart position End position 
espG 829165 830361 1197
espZ 841896 842221 326
espH 847765 848295 531
map 849134 849745 612
espF 861663 862283 621IE6 1549768 1568027 18260IE5 1879645 1885304 5660PP6 3411058 3417094 6037IE2 3705811 3720184 14374PP4 3761499 3765510 4012PP3 3985969 3986516 548PP2 4078295 4082262 3968
2.5 Growth and viability of effector mutant EPEC strains
The growth of EPEC2, EPEC1 and EPEC0 and the parental EPECwt was compared in liquid LB cultures, showing an identical growth curve (Figure 16A). We also measured the viability (CFU/OD) of EPEC2, EPEC1 and EPEC0 and the parental EPECwt in DEMEM after 2.5h, serial dilutions were plated in LB plates in triplicate 
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Figure 15. PCRs to confirm deletion of effectors in EPEC0. Electrophoresis gel of 
PCR products amplified from EPECwt and EPEC0. The amplicons corresponding to LEE effector genes or clusters deleted are indicated in the top of the gel. The order of the deletions from 1 to 13 is numbered. DNA ladder is labeled on the left.
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to count the number of CFU per O.D. All strains had a similar viability (Figure 16B). We also inspected bacteria from DMEM cultures by immunofluorescence microscopy after staining with anti-intimin-280, which revealed a similar size and morphology of all bacterial strains (Figure 15C).  Therefore the deletion of all effectors in the genome of EPEC did not affect growth, viability and morphology of bacteria.
3. Evaluation of T3SS injectisome functionality in effector mutant EPEC 
strains
3.1 Secreted protein by effector mutant EPEC strains.
To confirm the functionality of the T3SS after gene deletions we first analyzed the 
proteins secreted in the extracellular medium of effector mutant EPEC strains. Bacteria from parental and effector deletion strains were grown in DMEM at 37oC and the presence of secreted EspABD translocator proteins analyzed by SDS-PAGE. 
EPEC∆escN was used as a negative control (Figure 17). We found that secretion 
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Figure 16. Growth curve, viability and morphology of EPEC effector mutant 
strains. (A) EPECwt, EPEC2, EPEC1 and EPEC0 were grown in LB and we measured the optical density (O.D) at 600nm at the indicated times points. (B) CFU/OD of the indicated strains (EPECwt, EPEC2, EPEC1 and EPEC0) grown in DMEM and plated in LB-
agar.(C)Immunofluorescence microscopy of EPECwt, EPEC2, EPEC1 and EPEC0. EPEC 
strains are stained with anti-intimin-280 polyclonal serum (green). Scale bar 2 μm.
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of translocator protein EspABD was unaffected in the effector mutant strains. As 
expected EspC was absent after IE5 deletion in EPEC8.
3.2 Expression of injectisome-proteins in effector mutant EPEC strains
We also evaluated the expression of the structural proteins EscC, EscJ, EscD and the translocator protein EspB in all mutant strains by analyzing whole cell protein 
extracts by Western blot (Figure 18).  All the effectors mutant strains have equal 
expression of the injectisome-proteins compared to EPECwt. Therefore, deletion 
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Figure 17. Proteins secreted by EPECwt and derived mutant strains. 
Coomassie staining of proteins found in the extracellular medium, after 4 h of growth in DMEM at 37oC. The translocators EspABD and the autotransporter EspC are labeled. Molecular standards mass proteins are shown in kDa. 
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Figure 18. Expression of injectisome-proteins in EPEC effector mutant 
strains. Bacteria from the indicated strains were grown in DMEM at 37 oC during 
4 h and whole-cell  protein extracts analyzed by Western blot. Rabbit polyclonal 
antibodies were used to detect EscC, EscJ, EscD structural proteins and EspB translocator protein. Detection of cytoplasmic GroEL was used as a loading control.
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of effector genes did not affect the expression of injectisomes. These results, 
along with the secretion of translocator proteins into the extracellular medium, indicated the correct assembly of the T3SS injectisomes in the effector mutant strains generated. 
3.3. Infection of HeLa cells by effector mutant EPEC strains.
When EPEC bacteria adhere in vitro to cultured cells there is accumulation of actin 
filaments in the cytoplasm beneath the adherent bacteria, due to a signal cascade generated by Intimin-Tir interaction (Kenny, DeVinney et al. 1997). This recruitment of actin beneath the attached bacteria induces pedestals-like structures similar to those observed in vivo in A/E lesions (Knutton, Baldwin et al. 1989). Thus, to investigate whether effector mutant EPEC strains were able to translocate Tir into the cytoplasm of the cells and induce the actin accumulation underneath the adherent bacteria, we infected HeLa cells (Figure 19) with EPECwt and the derived 
EPEC2 EPEC0WT EPEC1
A
ct
in
In
tim
in
M
er
ge
Figure 19. Infection of HeLa cells with EPECwt and effector mutant EPEC 
strains. Immunofluorescence confocal microscopy of HeLa cells infected 1.5 h using a MOI 200:1 with EPECwt, EPEC2, EPEC1 and EPEC0 strains. EPEC is labeled with anti-intimin-280 serum (green), actin is labeled with TRITC phalloidin (red) and cell nuclei are labeled with DAPI (gray). Actin polymerization beneath 
the adherent bacteria is observed in EPECwt, EPEC2 and EPEC1. Scale bar 5 μm.
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effector mutant strains. Cultured HeLa cells were infected during 1.5 h and then 
fixed and stained for immunofluorescence microscopy. Actin accumulation was 
present in EPECwt, EPEC2 and EPEC1 but, as expected not in EPEC0 due to absent of tir. All other mutant strains also produced actin polymerization upon infection 
(data not shown). These results confirm that the individual translocation of Tir 
by EPEC1 is sufficient to induce actin accumulation during in vitro infection of HeLa cells. We also observed the typical microcolonies of the EPEC infection in all mutant strains, formed by the interaction between the bacteria through the BFP (Ramer, Bieber et al. 1996), indicating that this EPEC phenotype was not disrupted. 
3.4 Deletions of Intimin in EPEC2 and EPEC1.
Intimin is necessary to induce actin polymerization underneath the attached 
bacteria (Jerse, Yu et al. 1990). We deleted eae, the gene encoding intimin, in 
EPEC2 and EPEC1 to confirm that the actin accumulation seen underneath these bacteria depends on the interaction of intimin with translocated Tir. We analyzed 
the extracellular secreted proteins of the EPEC2 and EPEC1 ∆eae mutant strains compared to EPECwt (Figure 20A). Western blot of the bacterial lysates proved deletion of eae in EPEC2 and EPEC1 ∆eae strains (Figure 20A). We infected HeLa 
cells with EPEC2 and EPEC1 and the isogenic ∆eae mutant strains, to confirm formation of actin-pedestals by these strains. Whereas EPEC2 and EPEC1 bacteria infect HeLa cells and induce actin polymerization underneath the microcolonies, 
the isogenic ∆eae mutant strains do not induce actin polymerization underneath 
the attached bacteria. Also, microcolonies of ∆eae mutants are smaller than those of parental strains (Figure 20B). These results confirm that the effector mutant strains induce actin pedestals behind the attached bacteria that depend on the interaction of intimin and translocated Tir. 
3.5. Quantification of β-lactamase translocation into HeLa cells by effector 
mutant EPEC strains
We tested the capability of the EPEC effector mutant strains for protein 
translocation into HeLa cells using the reporter enzyme β-lactamase (Bla) (Figure 21). For this aim, we used pEspF1-20-Bla plasmid, which has the N-terminal 20 amino acids of the EspF effector protein fusion to Bla to drive its T3S-dependent translocation (Charpentier and Oswald 2004, Blanco-Toribio, Muyldermans et al. 2010). We tested translocation of EspF1-20-Bla by EPECwt, EPEC2, EPEC1 and 
EPEC0. As a negative control we used EPEC∆escN with the pEspF1-20-Bla and the EPECwt harboring pCX340. The pCX340 plasmid has the Bla reporter without 
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Figure 21. Translocation of β-lactamase (Bla) by EPEC effectors mutant stra-
ins. (A) Representation of Bla translocation through the T3SS injectisome of EPEC. EspF1-20-Bla fusion is translocated into the mammalian cell. The non-fluorescent 
Bla substrate (CCF2/AM) is modified by cytoplasmic esterases to the green fluo-rescent substrate CCF2. CCF2 hydrolysis by Bla results in a shift of green to blue 
fluorescence. (B) HeLa cells were infected 1.5 h and then incubated with CCF2/
AM for additional 1 h. Bla activity was quantified measuring the emission ratio 
of fluorescence at 450/520 nm in HeLa cells infected with the indicated bacte-
rial strains. Results are the mean of three independent experiments with stan-dard deviation (SD).  One way ANOVA Tukey’s Multiple Comparison Test. **p<0.01
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Figure 20. Deletion of eae in EPEC2 and EPEC1 strains. (A) Coomassie staining of 
proteins secreted in the extracellular media. EPECwt, EPEC2Δeae and EPEC1Δeae were grown in DMEM at 37oC during 4 h. The translocators EspABD and the autotransporter EspC are labeled. Protein standards for SDS-PAGE in kilodaltons (kDa) are shown. Western blot of bacterial lysates: detected with rabbit polyclonal anti-intimin-280, GroEL (as a loading control). (B) Immunofluorescence confocal microscopy of 
HeLa cells infected 1.5 h with EPEC2, EPEC2Δeae, EPEC1 and EPEC1Δeae (MOI 200:1). EPEC is labeled with anti-intimin-280 serum (green), actin is labeled with 
TRITC phalloidin (red) and cell nuclei are labeled with DAPI (gray). Scale bar 5 μm
RESULTS91
the signal for T3 secretion. HeLa cells were infected with these strains then were incubated with the CCF2/AM Bla substrate. This substrate goes into the cell in a 
passive mechanism and became fluorescent (green) by the action of eukaryotic esterases, translocation of Bla into the cytoplasm of the HeLa cells lead to the 
hydrolysis of CCF2 changing its fluorescence emission from 520 nm (green) to 450 
nm (Blue), which can be quantified using a fluorimeter. The emission ratio between 450 nm and 520 nm indicated the level of Bla translocation. We found that all 
strains, except the negative control DescN, translocate EspF1-20-Bla efficiently into HeLa cells, although small differences in level of translocation were observed. For instance, EPEC1 strain, which is devoid of espZ, appears to translocate more Bla than EPECwt, EPEC2 and EPEC0 strains. Conversely, EPEC0, which lacks Tir and intimate adhesion, translocated less Bla than the other strains. 
4. Deletion of myosin-interacting domain of EspB in the effector mutant EPEC 
strains
The main function of EspB is the formation of the translocation pore in the plasma membrane of the host cell for translocation of effectors (Taylor, O’Connell et al. 1998). It has been reported that EspB binds to myosins, which are a superfamily 
of proteins that interacts with actin filaments and mediate essential cellular processes, like microvilli formation and phagocytosis. EspB binding to myosins mediates the microvilli effacement and phagocytosis inhibition induced by this protein. Thus, deletion of the myosin-interacting domain (mid) of EspB disrupts the microvillus effacement and the inhibition of phagocytosis.  It has been reported that deletion of the mid of EspB does not affect the T3SS function and the induction of actin polymerization in the infected host cell (Iizumi, Sagara et al. 2007). With the aim of eliminating the effector function of EspB in the effector-less EPEC strain, we did an in frame deletion of the mid of EspB, encoded between amino acids 159-
218 (Iizumi, Sagara et al. 2007). After generation of a ∆mid mutant allele of espB, 
we generated strains EPEC0∆mid and EPEC2∆mid. EPEC0∆mid is the effector-less EPEC strain, whereas deletion was also done in EPEC2, because it still induces 
actin polymerization into HeLa cells, allowing us to test whether EspB∆mid affects 
Tir translocation. We infected HeLa cells with EPEC2, EPEC2∆mid, EPEC0 and 
EPEC0∆mid (Figure 22) and observed actin polymerization beneath the adherent 
bacteria in EPEC2 and EPEC2∆mid. EPEC0 and EPEC0∆mid bound to the HeLa cells 
and, as expected, they did not induce actin polymerization. Thus deletion of the mid of espB does not abrogate the ability of EPEC2 strain to translocate Tir. However 
we observed fewer bacteria adhered to HeLa cells infected with EPEC2∆mid 
and also smaller microcolonies. We quantified protein translocation by EPEC2, 
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EPEC2∆mid, EPEC0 and EPEC0∆mid using Bla translocation assay. We found that 
Bla translocation was significant lower in EPEC2∆mid and EPEC0∆mid compared to their parental strains (Figure 23). 
Hence, although EspB∆mid deletion does not completely disrupt T3SS-dependent translocation, it severely reduces the amount of protein translocation. Therefore, 
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Figure 22. Infection of HeLa cells by EPEC effector mutants expressing 
EspB∆mid. Immunofluorescence confocal microscopy of Hela cells infected 
1.5 h using a MOI 200:1 with EPEC2, EPEC2Δmid, EPEC0 and EPEC0Δmid. EPEC is labeled with rabbit polyclonal anti-intimin-280 serum (green), actin is labeled with TRITC phalloidin (red) and cell nuclei are labeled with DAPI 
(gray). Actin polymerization is indicated with white asterisks. Scale bar 10 μm.
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Figure 23. Translocation of Bla into HeLa cells by EPEC effector mutant 
EspB∆mid. HeLa cells were infected 1.5 h and then incubated with CCF2/AM for 
additional 1 h. Bla activity was quantified measuring the emission ratio of fluo-rescence at 450/520 nm in HeLa cells infected with the indicated bacterial stra-
ins. Results are the mean of three independent experiments with standard de-viation (SD).  One way ANOVA Tukey’s Multiple Comparison Test. ***p<0.001
RESULTS93
to maintain an efficient translocation of proteins the EPEC effector mutant strains required the presence of the mid region of EspB.
5. EspZ downregulates cytotoxicity and Tir translocation levels in HeLa cells 
infected with effector mutant EPEC strains
EPEC translocates effector proteins to subvert host cellular functions in a way 
that suits its infection. Because an excess in effector translocation leads to severe 
cytotoxicity, EPEC employs mechanisms that regulate the intracellular concentration of effectors.  EspZ has been reported to downregulate the translocation of EPEC 
effectors during infection. An EPECΔespZ has higher cytotoxicity during infection of HeLa cells, inducing high level of lactate dehydrogenase (LDH) release compared to EPECwt strain (Berger, Crepin et al. 2012). We wanted to evaluate the role of EspZ in the EPEC effector mutant strains during infection of HeLa cells.  
5.1 LDH-release in HeLa cells infected with effector mutant EPEC strains
We infected HeLa cells with EPECwt, EPEC2, EPEC1, EPEC0, and with the mutant 
EPECΔespZ, which was previously constructed with ΔespZ-2 allele (see Figure 13). 
To measure cytotoxicity we used the LDH-release as an indicative of damage in the 
cell plasma membrane.  As expected, EPECΔespZ induced a significant release of LDH compared to uninfected cells or cells infected with EPECwt, which induce low LDH-release (Berger, Crepin et al. 2012). EPEC2 and EPEC0 show low LDH-release 
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Figure 24. Host cells LDH-release after infection with EPEC effector mutant 
strains. Percentage of LDL-release compare to the total LDH-release of cells lysed 
with triton. HeLa Cells were infected for 3 h with EPECwt, EPECΔespZ, EPEC2, EPEC1 
and EPEC0. Uninfected (UI) cell were used as a control. Cytotoxicity was measured quantifying the level on LDH release into the culture supernatants in the last 1.5 h of 
the infection. Results are the mean of three independent experiments with standard deviation (SD).  One way ANOVA Tukey´s Multiple Comparison Test. ***p<0.001
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similar to the levels released by EPECwt. In contrast EPEC1 shows a significant increase in LDH-release compared to EPECwt, EPEC2 and EPEC0 (Figure 24). 
These data suggest that the lack of espZ in EPEC1 could deregulate protein translocation by the injectisome and leads to a higher level of translocation of the only remaining effector present in EPEC1, (i.e. Tir). Therefore, the absence 
of EspZ in EPEC1 may increase the cytotoxicity in HeLa cells due to an excessive translocation of Tir.
5.2 Levels of Tir translocated into HeLa cells infected with effector mutant 
EPEC strains
We measured the amount Tir translocated by our strains during infection of HeLa cells. For this purpose we performed 3 h infection of HeLa cells with EPECwt, 
EPEC∆escN, EPEC0, EPEC1 and EPEC2. We prepared cellular lysates of HeLa cells and analyzed Tir level by Western blot (Figure 25). We found Tir in HeLa cells 
infected with EPECwt, EPEC2 and EPEC1 but not in cells infected with EPEC∆escN and EPEC0 strains. Interestingly, the translocated levels of Tir were much higher in EPEC1 than in EPEC2 and EPECwt strains demonstrating that absence of EspZ increase the level of translocated Tir. In addition, the levels of Tir in cells infected 
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Figure 25. Levels of Tir translocated in HeLa cells by effectors mutant EPEC stra-
ins. Western blot of cell lysates with anti-Tir mAb . HeLa infected for 3 h with EPE-
Cwt, EPEC∆escN, EPEC0, EPEC1 and EPEC2. Uninfected (UI) HeLa cells were used as 
control. Quantification of Tir band intensity in the indicated strains. Results are the 
mean of three independent experiments with standard deviation (SD). 1 way ANOVA Tukey´s Multiple Comparison Test. **p<0.01, ***p<0.001.
RESULTS95
with EPEC2 were lower than those found in cells infected with EPECwt. Small differences in protein translocation levels found between EPECwt and EPEC2 strains (Figure 21) may explain, at least partially, the difference in the levels of Tir in infected HeLa cells.  Nonetheless, this result may also suggest that additional effector(s) that are absent in EPEC2 could be necessary to stabilize Tir in the infected cell. 
6. Translocation of individual LEE and non-LEE effectors by the effectors 
mutant EPEC strains
We wanted to evaluate the translocation of individual effectors in our effector 
mutant strains. In order to maintain physiological expression levels, we reintegrated a single copy of the effector gene of interest in its native location in the chromosome of EPEC2, EPEC1 and EPEC0, using suicide vectors with homology 
regions flanking the corresponding effector gene (Figure 8). Hence, similarly to gene deletion strategy, we followed a marker-less strategy for gene integration that 
preserves genome context and native regulatory elements (i.e., promoters, RBS, terminators) of effector genes. We followed this strategy to integrate effectors espH and map in the LEE and nleC in PP4.  
6.1. Translocation of EspH induces focal adhesions disassembly and cell 
rounding
EspH is one of the LEE-encoded effectors, that modulate host actin cytoskeleton (Tu, Nisan et al. 2003). EspH induces focal adhesions (FAs) disassembly (Wong, 
Clements et al. 2012). FAs are dynamic complexes of proteins that are localized at 
the site between the cell and the extracellular matrix (ECM) (Sastry and Burridge 
2000). Vinculin is a protein associated to these protein complexes (Humphries, Wang et al. 2007). We evaluated whether the translocation of EspH into HeLa cells by effector mutant EPEC strains complemented with espH in the chromosome induced FAs disassembly. Cultured HeLa cells were infected with EPECwt and with EPEC2, EPEC1 and EPEC0 with and without espH integrated and stained to 
visualize actin and vinculin by immunofluorescence microscopy (Figure 26). 
This experiment showed that EPECwt, EPEC2+espH and EPEC1+espH induced disruption of the FAs in the infected cells, whereas HeLa cells infected with strain lacking espH did not induce FAs disassembly, showing a vinculin staining pattern similar to UI control cells (Figure 26). Under these conditions of infection 
EPEC0+espH did not induce disassembly of FAs likely due the weaker cell attachment 
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of this strain. A dramatic cell rounding phenotype also evidences the disruption of the host actin cytoskeleton by EspH (Dong, Liu et al. 2010, Wong, Clements et al. 
2012).  We quantified HeLa cell rounding by the individual translocation of EspH after 2 h and 3 h of infection with EPECwt and effector mutant strains (Figure 27).
After 2 h of infection, EPECwt induces a clear cell rounding phenotype in 36% of 
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Figure 26. Individual translocation of EspH by effectors mutant strains induces 
FAs disassembly. Immunofluorescence confocal microscopy of HeLa cells infected 1 h plus 1 h with gentamicin treatment  (MOI 100:1), with EPEC2, EPEC1 and EPEC0 and isogenic strains with espH integrated in the chromosome. Control of uninfected (UI) and cells infected with EPECwt are shown. Vinculin was detected with anti-vinculin antibody (green) and actin was labeled with TRITC phalloidin (red).
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cell rounding. (A) Percentage of cell rounding on HeLa cells infected during 2 h (1 h with gentamicin treatment) (MOI 100:1) and 3 h (MOI 200:1), with EPEC2, EPEC1 and EPEC0 with espH integrated in the chromosome and with the isogenic control strains without espH. Control of uninfected (UI) and cells infected with EPECwt are shown. One hundred cells were counted in triplicate. Results are the mean of three 
independent experiments with standard deviation (SD). (B) Immunofluorescence microscopy of HeLa cells infected 2 h (1 h with gentamicin) and 3 h with the indicated bacterial strains. Actin was labeled with TRITC phalloidin (red).
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the cells whereas EPEC2 and EPEC0 strains do not induce cell rounding. EPEC1 induces cell rounding in 7% of the cells and this small increase in cell rounding 
compared to EPEC2 and EPEC0 is likely caused by the cytopathic effect of an excess 
of translocated Tir. The strains EPEC2+espH and EPEC1+espH induce higher levels of cell rounding, in 21% and 53% of the cells, respectively. The high level of cell 
rounding caused by EPEC1+espH could be due to higher levels of Tir and EspH 
translocation. Under these infection conditions (2 h) EPEC0+espH induced low levels of cells rounding (i.e. 7% of the cells). Longer infection of 3 h increased the cell rounding phenotype in all strains with espH, including EPE0+espH (Figure 27A). Importantly, HeLa cells infected with EPEC2 and EPEC0 remained well attached after 3 h of infection, with similar appearance to uninfected control cells (Figure 27B). After 3h of infection, EPEC1 strains showed severe cytopathic effect on HeLa cells and also induced high level of cell detachment (Figure 27B). Together, these results demonstrate that effector mutant EPEC strains were able to translocate 
functional EspH from chromosomal expression. 
6.2. Translocation of Map induces filopodia
The mitochondrial associate protein (Map) is a multifactorial effector that 
induces filopodia in the cell surface at early time of infection and mitochondrial dysfunction at late time of infection (Papatheodorou, Domanska et al. 2006, Berger, Crepin et al. 2009). Filopodia are thin, actin-rich plasma membrane protrusions like spikes associated with the infecting microcolonies in the cell surface (Mattila 
and Lappalainen 2008, Berger, Crepin et al. 2009). Cultured fibroblast Swiss 3T3 cells were infected for a short time (10 min) with EPEC2, EPEC1 and EPEC0 strains and isogenic strains with a single copy of map in its endogenous gene locus. In this 
experiment we centrifuged the plate with the cells and bacteria at the beginning of the infection to synchronize infection and increase early cell contacts even in 
EPEC0 strains. Actin staining of infected cells for immunofluorescence microscopy 
revealed the induction of filopodia by the effector mutant EPEC strains carrying 
map (Figure 28). 
This indicates that individual translocation of Map, from chromosomal expression, 
induces filopodia formation similar to the reported filopodia associated with 
EPECwt microcolonies (Jepson, Pellegrin et al. 2003, Huang, Sutton et al. 2009). 
RESULTS99
EP
EC
2
EP
EC
2+
m
ap
EP
EC
1
EP
EC
1+
m
ap
EP
EC
0
EP
EC
0+
m
ap
O127 Actin Merge
Figure 28. Individual Translocation of Map by effector mutant strains 
induces filopodia. Immuno fluorescence microscopy of 3T3 cells infected for 10 min with EPEC2, EPEC1 and EPEC0 and isogenic strains with map integrated in the chromosome. EPEC was detected with rabbit polyclonal anti 0:127 (red) and actin was stained with Orego-green phalloidin (green). Filopodia 
like spikes (arrowheads). Actin-polymerization (arrows). Scale bar 2 μm.
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6.3. Translocation of NleC degrades p65 of the NF-κB complex
During EPEC infection different effectors are used by the pathogen to block the 
Nf-κB proinflammatory pathway (Newton, Pearson et al. 2010, Li, Zhang et al. 
2013). NleC degrades p65 component of NF-κB to decrease the cytoplasmic levels, 
disrupting p65 nuclear translocation and cytokine gene expression (Pearson, Riedmaier et al. 2011). It has been postulated that NleC preferentially targets 
free p65 released from the IκB complex, although it can also degrade bound p65 (Pearson, Riedmaier et al. 2011). The nleC gene was reintegrated in its native locus 
of the chromosome of EPEC2, EPEC1 and EPEC0. Next, we infected HeLa cells (Figure 29) for 1 h, and then cells were washed and incubated for additional 3 
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Figure 29. Translocation of NleC by EPEC effectors mutant strains induces p65 
degradation. (A) Western blot displaying p65 of HeLa cells infected for 4h (3 h with gentamicin) with EPEC2, EPEC1 and EPEC0 with nleC integrated in the chromosome and with the isogenic parental strains without nleC and EPECwt.  Uninfected (UI) cell used as control. Cell lysates were analyzed by Western blots and p65 was detected with 
rabbit polyclonal anti NF-κB p-65. α-tubulin was used as a loading control and it was detected with mouse monoclonal anti-alpha tubulin. (B) Quantification of p65 in Hela 
cells infected with the indicated strains. Protein loading was normalized with α-tubulin. 
Results are the mean of three independent experiments with standard deviation (SD). One way ANOVA Tukey´s Multiple Comparison Test. **P <0.01, ***P <0.001.
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h with gentamicin in DMEM. Western blots of the cell lysates revealed that p65 was proteolysed in cell infected with the effectors mutant strains carrying nleC. Proteolysis of p65 in effectors mutant strains carrying nleC was higher than that induced by the EPECwt strains, likely caused by the presence of other effector in 
the wild type strains which prevent IκB degradation.
7. Evaluation of A/E formation in human biopsies by the effector mutant 
EPEC strains
The previous results with HeLa cells indicated that all effector mutant strains 
carrying Tir are able to induce reorganization of the actin filaments in pedestal-like structures, underneath the attached bacteria. This includes EPEC1, which carries Tir in the absence of all other effectors.  Hence, we wanted to evaluate whether these EPEC effectors mutant strains were also able to induce A/E lesion formation in human intestinal biopsies, a model closer to natural human infection.
7.1.  EPEC2, EPEC1 and EPEC0 do not induce A/E lesion in human intestinal 
biopsies
We infected human intestinal biopsies with the effector mutant EPEC strains. After 
8 h of infection, biopsies samples were thoroughly washed, fixed and analyzed by scanning electron microscopy (SEM) to determine the presence of A/E lesions. As previously described (Introduction), A/E lesions are characterized by microcolony formation, brush border microvilli disruption at the site of the infection, and elongation of the microvilli in the periphery of the microcolony (Figure 30).  To avoid false positive results we carefully inspected the mucosa surface, avoiding damaged 
areas that could induce no specific adhesion of the bacteria to the enterocytes. With this analysis we found that EPECwt induces A/E lesion in 76% of the infected biopsies, whereas EPEC0 control did not show A/E lesion formation in none of the infected biopsies (Table 8). Interestingly EPEC2 and EPEC1 strains were no able to induce the A/E lesion in human intestinal biopsies, despite inducing actin polymerization in HeLa cells. These results indicate that other effectors besides Tir and EspZ are essential to induce the A/E lesion formation. 
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Table 8. Human biopsies infected by EPECwt and EPEC effector mutant strainsStrain Effectors genes remaining Number of positive bi-opsieswith A/E lesionPositive/Total (%)WT all 13/ 17 (76)EPEC2 espZ and tir 0/6 (0)EPEC1 tir 0/6 (0)EPEC0 none 0/5 (0)EPEC9 espZ+tir+IE2+IE5+IE6+PP2+PP3+PP4+PP6*    5/6 (83)EPEC2-LEE+ espZ+tir+map+espH+espF+espG 0/5 (0)     * Encoded effectors in IEs and PPs  
EPEC2
EPEC1 EPEC0
WT
*
EPEC2+LEEEPEC9
*
Figure 30. Infection of human duodenal biopsies infected with EPECwt and effectors 
mutant strains: EPEC2, EPEC1, EPEC0, EPEC9 and EPEC2-LEE+ analyzed by SEM. EPECwt and EPEC9 induce the characteristic A/E lesion in the intestinal mucosa surface: with bacterial microcolony (asterisk) and microvilli elongation in the periphery of the microcolony (arrowheads). The biopsies infected with EPEC2, 
EPEC1, EPEC0 and EPEC2-LEE+ lack of adherent bacteria and A/E lesions, showing 
normal microvilli on enterocyte surface of human biopsies. Scale bar 2 μm
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7.2. Non-LEE effectors are essential for the induction of A/E lesion in human 
biopsies
To characterize whether LEE or non-LEE effector(s) were needed to induce A/E lesion in human intestinal biopsies assay we performed infections with the effectors mutant strains EPEC9 and EPEC2-LEE+ (Figure 30). EPEC9 strain maintains two LEE effectors (EspZ and Tir) and the whole repertoire of non-LEE effectors found in EPECwt. EPEC2-LEE+ is a strain derivative of EPEC2 (espZ+ tir+), in which we introduced the deleted LEE effectors (espG, map, espF, espH) to reconstitute a wt LEE, but that is devoid of all the repertoire of non-LEE effectors found in EPECwt. Infection of human biopsies revealed that EPEC2-LEE+ strain is unable to induce 
efficient A/E lesion formation whereas EPEC9 strain induces A/E lesion formation at levels similar to EPECwt (Table 8). In all experiments we infected human biopsies 
with EPECwt to have positive controls of A/E lesion, which explains the higher number of biopsies infected with this strain. Hence, these results indicate that non-LEE effectors are essential to induce the of A/E lesion formation in human intestinal biopsies.
To characterize the non-LEE effector(s) participating in the A/E lesion formation, we analyzed infection of human biopsies with strains having sequential deletions of the clusters of effectors genes present in integrative element: IE5, IE6 and IE2 (Table 9). While deletion of IE5 (EPEC8) did not have a significant effect on A/E lesion formation, the percentage of A/E positive biopsies decreased to 54% with deletion of IE6 (EPEC7) and to 23% by the deletion of IE2 (EPEC6). 
Table 9. Human biopsies infected by EPEC effector mutant strainsStrain Effectors genes remaining Number of positive biopsieswith A/E lesionPositive/Total (%)EPEC9 espZ+tir+IE2+IE5+IE6+PP2+PP3+PP4+PP6* 9/11(82%)EPEC8 espZ+tir+IE2+IE6+PP2+PP3+PP4+PP6* 10/14(71)EPEC7 espZ+tir+IE2+PP2+PP3+PP4+PP6 * 7/13(54)EPEC6 espZ+tir+PP2+PP3+PP4+PP6 * 3/13(23)
EPEC7∆nleE2 espZ+tir+ lifA-like+PP2+PP3+PP4+PP6 * 7/11(64)
EPEC7∆efa1/
lifA-like espZ+tir+ nleE2+PP2+PP3+PP4+PP6 * 4/12(33)    * Encoded effectors in IEs and PPs  
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The dramatic reduction in the efficiency of A/E lesion formation in EPEC7 and EPEC6 strains indicates that deletion of IE6 and IE2 notably reduces the capacity of EPEC to induce the A/E lesion formation in human biopsies. Interestingly, EPEC6 strain having only PPs encoded-effectors was still capable of inducing A/E lesion formation in 23% of samples analyzed. This indicates an additive role of the non-LEE encoded effectors. The IE6 and IE2 have almost identical clusters of effectors genes. IE6 carries one copy of espL, nleB1, nleE1 and efa1/lifA whereas IE2 carries a pseudogene copy of espL* and nleB*, one copy of nleE2 and one copy efa1/lifA-like, a gene homolog of efa1/lifA (Figure 31A). This suggests that the copies of nleE and/or efa1/lifA homologs could play a major role in A/E lesion formation. To investigate this possibility we generated individual deletions of efa1/lifA-like and 
nleE2 of the IE2 in EPEC7, which already has a deletion in IE5 and IE6 (Figure 31A). 
Human biopsies infected with EPEC7∆nleE2 strain (carrying a single functional copy of efa1/lifA-like) induced A/E lesion in 64% of the infected biopsies, similar to EPEC7. On the contrary, deletion of efa1/lifA-like in EPEC7 reduced the A/E lesion formation to 33% of the infected biopsies similar to EPEC6 (Table 9). We 
confirmed by RT-PCR that deletion of nleE2 or efa1/lifA-like have no polar effects 
on the expression of the remaining genes in the IE2 (Figure 31B). These results indicate that deletion of efa1/lifA-like has a major impact on A/E 
lesion formation, explaining the low efficiency of A/E lesion formation in EPEC6. Collectively, these results demonstrate the requirement of non-LEE effectors for A/E lesion formation, with an additive role of effectors encoded in integrative elements (IEs) and prophages  (PPs), and suggest a major role of efa1/lifA proteins in this process. 
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Figure 31. Deletion of nleE2 and efa1/lifA-like in EPEC7. (A) Clusters of IEs encoded-effectors in IE5, IE6 and IE2. Red bars indicated deletion of IE5 and IE6 encoded-effectors and individual deletion (nleE2 and lifA-like) in EPEC7∆nleE2 and EPEC7∆lifA-
like. (B) Electrophoresis gel of RT-PCR products of expression of lifA-like and nleE2 in 
effectors mutant strains. EPEC7∆lifA-like has expression of nleE2 and EPEC2∆nleE2 has 
expression of lifA-like. EPEC7 has expression of lifA-like and nleE2. EPEC6 does not have 
expression of lifA-like and nleE2. The expression of tir was used as a control for RT-PCR.
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Generation and characterization of the effector mutant EPEC strains 
EPEC as other pathogens uses its T3SS to translocate effectors proteins 
into the cells to subvert host cellular functions. EPEC was the first E. coli pathogen to be associated with human disease and many studies have investigated the role EPEC effectors. In this PhD thesis we generated several effector mutant strains with the aim of further characterizing the role of EPEC T3SS effectors in infection and broaden the knowledge about EPEC colonization of human intestinal mucosal surface. In addition, the attenuation of the effector mutant EPEC strains could be of biotechnological interests, for instance for the development of an EPEC vaccine and for the delivery of therapeutic proteins into enterocytes of human intestine.  Since our objective was to make multiple deletions in the genome of EPEC and 
reintroduce selectively specific effector(s) in the strain, we wanted the use 
an efficient deletion strategy that would allow us to made gene deletions and integrations in the genome without leaving antibiotic resistance markers or 
recombination sequences (“scars”) in the chromosome of the engineered strain. Several techniques allow genome engineering based in homologous recombination to delete and integrate target genes.  These techniques are based on generating a mutant allele in vitro and later introduce it in the bacteria to replace the target gene by homologous recombination.  Gene 
modification can be conducted introducing the mutant allele in the bacterium 
as a linear DNA fragment and expressing the λ Red genes for recombination, or cloned in a suicide plasmid that is integrated and resolved by means 
of  antibiotic resistance gene markers and counter-selection systems (e.g. sucrose/sacB) (Datsenko and Wanner 2000, Mizoguchi, Tanaka-Masuda et 
al. 2007). However, frequently these techniques leaves “scars” sequences after removal of antibiotic markers or the counter-selection system are not 
efficient in E. coli. We chose the markerless gene deletion strategy previously 
described by Posfai and colleagues (1999), which is based on the integration by a single homologous recombination event of a suicide plasmid carrying the mutant allele and I-SceI restriction sites. This co-integrate is resolved by a second intramolecular recombination event induced by the generation of a double strand break in the chromosome by cleavage of I-SceI restriction enzyme, which can be transiently expressed in the bacteria upon induction. 
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This methodology had been successfully employed to minimize the genome of E. coli K-12 strain (Posfai, Plunkett et al. 2006).
The prototypical EPEC strain E2348/69 has been widely studied using 
classical genetic and global “omics” approaches providing a good knowledge of the whole repertoire of effectors encoded in the genome of this strain 
(Iguchi, Thomson et al. 2009, Deng, Yu et al. 2012). Taking advantage of this information and the markerless gene deletion strategy based on I-SceI, we carried out the deletions necessary to build an effector-less EPEC strain 
(EPEC0) devoid of all known T3SS effectors. We successfully delete all the 
effectors genes reported in the chromosome of EPEC E2348/69 through 13 
deletions, being 326 bp the smallest deletion (espZ) and the 18260 bp the 
largest deletion (cluster of effectors in IE6). All the effector genes deleted were eliminated from the start to the stop codon, maintaining their original transcriptional promoters and terminator signals without leaving any scars in the chromosome. The only exception to this global approach was the deletion of espZ, in which deletion of its RBS was necessary to maintain 
correct expression levels of the downstream genes in the operon. We verified 
the deletions made in the genome by PCR and by whole genome sequencing 
comparison of the parental and the effector mutant strain EPEC1, in 
which Tir effector is still encoded. We sequenced EPEC1 genome because 
translocation of Tir to HeLa cells allowed us to confirm the functionality of T3SS in this strain.
A central objective of our strategy was to keep a functional T3SS in EPEC. 
Therefore, we decided to delete first the effector genes localized in the 
LEE island to evaluate whether any of these deletions could disrupt the correct assembly and functionality of the T3SS. The effector genes espZ and tir are also localized in the LEE but we left these two genes for the last two deletions because EspZ and Tir effectors are important to control physiological protein translocation levels and intimate bacterial attachment to host cells. It was previously reported that EspZ blocks effector protein 
translocation from a second wave of EPEC infection (Mills, Baruch et al. 
2008, Berger, Crepin et al. 2012). Therefore, we decided to maintain EspZ to have a controlled translocation of the remaining effector proteins during 
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the construction of the effector-less EPEC strain. Besides, tir was the last gene deletion because translocation of Tir is essential for intimate bacterial attachment and it is a helpful indicator of the functionality of the T3SS 
through its actin-polymerization phenotype upon translocation (Kenny, 
DeVinney et al. 1997). 
We confirmed that the multiple deletions generated in the chromosome of EPEC do not have deleterious effect on the growth of the bacterium, 
since EPECwt, EPEC2, EPEC1 and EPEC0 strains have the same growth 
rate, viability and cellular morphology in LB and DMEM media (Figure 
16).  We also evaluated after each deletion the correct assembly of the T3SS injectisome. The mutant strains were grown under induction conditions and 
the secretion of EspABD translocator proteins was confirmed by SDS-PAGE 
(Figure 17). The correct expression level of some structural proteins of the 
T3SS injectisomes, like EscC, EscJ, EscD and the translocator protein EspB 
was confirmed by Western blot in all the effector mutant strains (Figure 
18). Next, we infected HeLa cells with the EPECwt and the effector mutant 
EPEC strains to evaluate the functionality of the T3SS. EPEC2 (bearing espZ and tir) and EPEC1 (bearing only tir) were able to induce the actin-pedestal formation underneath the attached bacteria. This result allowed us to conclude that EPEC only needs the effector Tir to induce the actin-pedestal during infection of epithelial cells in vitro (Figure 19). As expected, the 
effector-less EPEC0 strain did not induce the actin polymerization because 
Tir is essential to start the actin polymerization cascade. We performed 
protein translocation assays of Bla to quantitate protein translocation in 
the effector mutant EPEC strains, including EPEC0 strain (Figure 21). All 
effector mutant strains translocate Bla fused to the N-terminal 20 amino 
acids of EspF (EspF
1-20
-Bla) into HeLa cells. EPEC2 translocates Bla at slightly reduced levels compared to EPECwt, but the difference was not statistically 
significant, suggesting that EspZ and Tir effectors alone are sufficient to control protein translocation at levels close to those found in EPECwt. On 
the contrary, EPEC1 translocates higher amounts of Bla than the EPECwt, likely due to the absence of the EspZ effector. It has been proposed that EspZ, which inserts in the host plasma membrane, controls protein translocation by interacting with an unknown bacterial protein via an extracellular loop, 
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which induces a conformational change at the N-terminus that interacts 
with EspD translocator blocking protein translocation (Berger, Crepin et 
al. 2012). EPEC0 reduces the level of Bla translocation into the cells likely because in the absence of intimate bacterial adhesion protein translocation 
is less efficient. This assay also allowed us to confirm that all effector 
mutant EPEC strains, including EPEC0, have a functional T3SS for protein translocation. 
The T3-secreted protein EspB is essential for the formation of the protein-translocation pore, but is also targeted to the cytoplasm of the infected cells 
and has effector function (Taylor, O’Connell et al. 1998, Luo and Donnenberg 
2011). EspB within HeLa cells induces redistribution of actin altering the 
cell shape (Taylor, Luther et al. 1999). EspB interacts with myosin within 
the cell through a central domain called mid.  Myosin proteins interact 
with actin filaments mediating essential cellular processes like microvillus 
formation and phagocytosis. EspB interaction with myosins is responsible of the microvilli disruption and phagocytosis inhibition. It was reported 
that an EPEC mutant with deletion of the mid domain of EspB maintains T3SS functionality but could not induce microvilli effacing or suppress 
phagocytosis (Iizumi, Sagara et al. 2007). In an attempt to delete all effector 
functions in the effector-less strain, we conducted deletion of the EspB 
mid domain in EPEC0 to generate EPEC0∆mid strain.  We did the same 
deletion in EPEC2 generating EPEC2∆mid to test translocation of Tir in 
this strain.  Infections of HeLa cells with these mutants (Figure 22) allowed 
us to confirm that EPEC2∆mid was able to translocate Tir, but the size of bacterial microcolonies was smaller compared with the parental strain 
EPEC2 indicating less adhesion of the bacteria to the cells. We evaluated the 
functionality of the T3SS performing Bla translocation assays to compare 
EPEC2, EPEC0 and their espB∆mid mutant strains (Figure 23), which 
showed that deletion of the mid domain of EspB strongly reduces protein translocation. Since our main objective was to maintain physiological levels of protein translocation in the effector mutant EPEC strains, we did not use strains with the espB∆mid deletion in our subsequent experiments. 
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It has been reported that EPEC ∆espZ strain is highly cytotoxic, likely due to 
deregulated translocation of protein effectors (Berger, Crepin et al. 2012). 
We observed that EPEC1 strain, which is devoid of EspZ, has an increased 
protein translocation of Bla.  Towards further characterize the role of EspZ 
effector we conducted a cytotoxicity assay to measure the level of LDH 
released from HeLa cells after infection with the effector mutant EPEC strains. 
We found not significant difference of LDH-release between uninfected cells 
and cells infected with EPECwt, EPEC2, and EPEC0. Importantly, we found 
that EPEC1 is highly cytotoxic and induces a strong LDH-release (Figure 24). 
Tir is the only remaining effector in EPEC1. Hence, we measured the level 
of Tir in HeLa cells after infection with the effector mutant EPEC strains. Tir 
was found translocated into HeLa cells by EPECwt, EPEC2 and EPEC1 and, 
as expected, was absent in cells infected with control strains (EPEC0 and 
EPEC∆escN). We found that EPEC1 injects significantly higher level of Tir 
into HeLa cells (Figure 25). This suggests that the cytotoxicity of EPEC1 could be due for this higher amount of Tir translocated into the cell. A possibility is that this uncontrolled translocation of Tir increases the number of Tir molecules inserted in the cell membrane allowing Intimin-Tir interaction and inducing an increase number of intimate attached bacteria to the cell. 
This “superinfection” should increase the number of T3SS injectisomes in contact with the cell and probably this high number of translocation pores 
is responsible for the cytotoxic effect of EPEC1, although direct cytotoxic effects due to high levels of Tir in the cytosol of the infected cell cannot be excluded. Interestingly, these experiments also reveal low levels of Tir in 
HeLa cells infected with EPEC2. The difference in Tir levels between cells 
infected with EPEC2 and EPEC1 emphasizes the role of EspZ to control 
protein translocation. Since EPEC2 did not show a strong reduction of 
protein translocation in the Bla assay, these results suggest that EPEC2 might be devoid of an effector that could potentially stabilize Tir in the 
infected cell. It is worth noting that the reduced amount of Tir found in HeLa 
cells infected by EPEC2 is sufficient to induce actin-pedestals that cannot be distinguished from those of the wild type strain (Figure 19). Collectively, these results further demonstrate that EspZ is able to downregulate protein translocation levels reducing the cytotoxicity associated to high levels of effectors and T3SS. 
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Translocation of EspH, Map and NleC using effector mutant EPEC 
strains
To understand bacterial virulence it is important to characterize bacterial effectors, their host targets and their mechanism of action. Several approaches have been used to study bacterial effector function in the host. The ectopic expression of an effector into eukaryotic cells by transfection is 
useful to get information about the effector phenotypes (Clements, Smollett 
et al. 2011, Wong, Clements et al. 2012). A different approach is to study the phenotype of mutant strains and to evaluate whether the strain recover its wild type phenotype by trans-complementation (Berger, Crepin et al. 2012, 
Wong, Clements et al. 2012). We wanted to test whether translocation of individual effectors from chromosomal single-copy reintegration in the effector mutant strains could reproduce phenotypes previously reported 
with mutant strains and transfection experiments. We chose EspH, Map and NleC effectors for these experiments since they target different cellular 
activities and were located in distinct loci in the LEE and outside the LEE 
(Berger, Crepin et al. 2009, Dong, Liu et al. 2010, Pearson, Riedmaier et 
al. 2011). Therefore, we reintegrated espH and map in the LEE and nleC in 
the PP4 in their original site and under native endogenous transcriptional 
control signals in EPEC2, EPEC1 and EPEC0.  
The Rho GTPases are important regulators of actin cytoskeleton and participate in important cellular processes as migration, adhesion, 
morphogenesis and phagocytosis (Schmidt and Hall 2002). The activation 
and inactivation of the Rho GTPases is regulated, among other mechanisms, 
by guanine nucleotide exchange factors (GEFs), which promote dissociation 
of GDP and subsequent binding of GTP (Wong, Clements et al. 2012). EspH 
effector directly binds RhoGEF, competing with Rho for binding to RhoGEF 
and preventing Rho activation. The actin cytoskeleton of the cell is link to 
the extracellular matrix through FAs, it has ben reported that EspH induces 
FAs disassembly (Wong, Clements et al. 2012). Ectopic expression of EspH and trans-complementation experiments from overexpressing plasmids 
have shown that EspH alters the cellular shape inducing cell rounding and 
detachment (Dong, Liu et al. 2010). We did immunofluorescence microscopy 
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of HeLa cells infected with the effector mutant EPEC strains with and without 
espH integrated in the chromosome (Figure 26 and 27). All the strains with 
espH are able to induce cell rounding and FAs disassembly. Also EPEC0+espH 
can induce cell rounding but in this case EPEC0 needs more time of infection to rich the translocated protein level necessary to induce the phenotype, 
because EPEC0 is devoid of Tir to help with the intimate attachment, 
which favors the translocation(Battle, Brady et al. 2014). With the effector 
mutant strains we demonstrated that the individual translocation of EspH 
was sufficient to induce FAs disassembly and cell rounding from native 
expression levels without the need the other effector(s).   
Map is a multifunctional effector protein that induces a transient filopodia formation at the site of bacterial attachment and also induces mitochondria 
dysfunction. These properties of Map are carried out in different domain 
of the protein, as mutation in the WxxxE motif of Map involved in filopodia 
formation abolished filopodia and did not interfere with Map targeting to 
the mitochondria (Alto, Shao et al. 2006).  Substitution of the N-terminal mitochondrial target sequence of map by the N-terminal signal of Tir 
abolishes mitochondrial localization and tolerates the filopodia formation 
(Kenny 2002). Map induces filopodia by mimicking GEF activity over the 
Cdc42 Rho small GTPase, which leads to actin cytoskeletal modification to 
induce filopodia formation (Huang, Sutton et al. 2009). Map has a TLR domain 
that allows its interaction with the PDZ1 domain of NHERF1, it is proposed that this induces recruitment of activated Ezrin leading to activation of the 
small GTPase RhoA and the posterior activation of RhoA/ROCK pathway for 
stabilization of the filopodia (Simpson, Shaw et al. 2006, Berger, Crepin et 
al. 2009). EPEC induces a fine modulation of actin cytoskeleton of the cell, 
as Tir induces filopodia downregulation. Intimin-Tir interaction induces 
activation of Tir and the recruitment of NcK. The latter has more affinity 
for N-WASP than Cdc42 and this sequesters N-WASP from the Cdc42-GTP 
pathway involved in filopodia (Tomasevic, Jia et al. 2007, Berger, Crepin et 
al. 2009). Additionally, Tir bound to NcK triggers local activation of GTPase-
activating proteins (GAPs) and this inactivates Cdc42 (Zhao, Ma et al. 2003). 
Another mechanism reported for filopodia withdrawal is the release after 
Intimin-Tir interaction of a GXLR motif in the C-terminal cytoplasmic 
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region of Tir, which possesses a GAP-like activity and induces the switch-
off of Cdc42 with the consequent filopodia downregulation (Kenny 2002). 
We did short-time infections of Swiss 3T3 cells with EPEC2, EPEC1 and 
EPEC0 with and without map integrated in the chromosome. Through 
actin staining of infected cells and immunofluorescence microscopy we found that all the strains with map in the chromosome were able to induce 
filopodia formation at the site of microcolony formation (Figure 28). For this assay we synchronized the infection with centrifugation to allow the 
attachment of EPEC0 at the same time than the rest of the EPEC strains and 
under these conditions EPEC0+map was able to translocate the amount 
of Map necessary to induce filopodia. Therefore, Map translocated from 
chromosomal expression was able to induce filopodia without the help of 
any other effector. Although, the relevance of filopodia formation during in 
vivo infections is not yet known, the study of EPEC effectors that directly 
and indirectly manipulates Rho GTPases is relevant, because of the vast 
number of cellular processes that are controlled by the small Rho GTPases 
(Kenny 2002). 
Infecting bacteria alert their presence to the host immune system through 
bacterial antigens. Hence, to escape from the host immune response, bacterial pathogens have acquired effectors that modulate the host immune 
response to allow the progression of infection (Takeuchi and Akira 2010). For instance, the OspG from Shiguella flexneri is reported to prevent phospho-
IκBα degradation and TNF-α-induced activation of NF-κB. It was reported that upon infection of ileal loops in rabbit, an ospG mutant induced stronger 
inflammatory response than the wt strain (Kim, Lenzen et al. 2005).  Also, the Salmonella SpvC T3 secreted effector is a phosphothreonine lyase that 
target MAPK in the nucleus. Mice infected with Salmonella enterica serovar Typhimurium lacking the spvC gene showed pronounced colitis when 
compared with mice infected with the wild-type strain(Haneda, Ishii et al. 
2012). 
The A/E pathogens EPEC, EHEC and Citrobacter rodentium also are endowed 
of effector proteins to targets the host immune response (Pearson, Riedmaier 
et al. 2011, Pham, Gao et al. 2012, Hodgson, Wier et al. 2015). In fact, EPEC 
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infection is characterize by a week inflammatory response (Dean and Kenny 
2009). It has been reported that EPEC translocates in a T3SS-dependet 
manner NleE, NleB, NleH1 and NleC to disrupt the NF-κB proinflammatory pathway. The NleC EPEC effector protein is widely characterized by 
disrupting the NF-κB pathway through the degradation of p65 transcription 
factor. NleC is reported to preferentially degrade active free p65 but it can 
also degrade IκB bound p65. NleB and NleE through different mechanism 
disrupt the NF-κB signaling pathway, preventing IκB degradation and 
the release of p65 from the NF-κB complex, hindering in this way the 
nucleation of p65. Several studies propose a model in which NleC function 
downstream of NleB and NleE to degrade the active p65 that scape from 
the NleB and NleE inhibition (Newton, Pearson et al. 2010, Yen, Ooka et al. 
2010, Pearson, Riedmaier et al. 2011). Our results after infecting HeLa cells 
with EPEC0+nleC revealed that the individual T3SS translocation of NleC is 
enough to decrease the total p65 of the infected cells. And also EPEC1+nleC 
and EPEC2+nleC were able to induce degradation of p65. This indicates that 
nleC reintegration in the chromosome allows the appropriate expression of nleC and that the three effector mutant EPEC strains translocates the 
amount of protein necessary to induce p65 degradation. EPECwt induces 
less degradation of p65 because the wild-type strain is endowed of NleB and 
NleE to avoid IκB degradation (Figure 29). As NleC degrades free p65 more 
efficiently, during EPEC-wt infection there is less free p65 to be degraded by 
NleC. This correlates with previous results (Pearson, Riedmaier et al. 2011) 
in which EPEC-wt need longer time to induce degradation of p65 than a 
∆nleE strain. It is significant to highlight that previous studies identified 
degradation of p65 by NleC with the strategy of loss of the function by the mutant strain and the gain of the function using plasmids complementation and also with ectopic expression of nleC. The effector mutant EPEC strains in our study translocate NleC from chromosomal native expression levels , 
which are sufficient for degradation of p65. 
It has been reported that Tir interaction with SPH-2 tyrosine phosphatase 
enhances their inhibitory association with TRAF6 preventing the NF-κB 
signaling pathway (Yan, Quan et al. 2013). This results remains controversial because strains lacking tir do not adhere well to the cell and this may affect 
DISCUSSION 116
the translocation of other effectors implicated in the immune response. Our 
results with EPEC1+nleC and EPEC2+nleC, both with tir in the chromosome and the former translocating high levels of Tir, suggest that Tir is not 
blocking the NF-κB signaling. Tir blocking the NF-κB pathway should reduce 
the release of p65 from the NF-κB complex, which should be evidenced by 
reduction in the p65-NleC degradation. In contrast, we found that the three effector mutant strains with nleC reduce the total p65 of the cells at the 
same level and this suggests that the same level of p65 released from NF-κB complex. All together, these data demonstrate that the effector mutant EPEC strains offer an optimal tool for translocation of physiological amounts of 
defined effector proteins to investigate EPEC infection.  
Infection of human intestinal biopsies using effector mutant EPEC 
strains
The pathogenic mechanisms of EPEC have been widely investigated through 
in vitro infection of cultured cell lines (Scaletsky, Pedroso et al. 1999, Kanack, 
Crawford et al. 2005, Nieto-Pelegrin and Martinez-Quiles 2009, Munera, 
Crepin et al. 2010, Glotfelty, Zahs et al. 2014). However, most cell lines used are nonpolarized and are not from intestinal origin. On the other hand, the study of EPEC infection in vivo is hindered because EPEC is a human-specific 
pathogen (Schuller, Chong et al. 2007). A surrogate model established to investigate the A/E pathogens infection in vivo is the mice infection by the mouse pathogen Citrobacter rodentium. A study with Citrobacter (Deng, 
Vallance et al. 2003) demonstrated that Citrobacter infection of cells in 
vitro requires Tir phosphorylation for actin-pedestal formation but Tir-
phosphorylation deficient mutants still colonize the mouse gut and induce A/E lesion and crypt hyperplasia. This highlights the necessity to use a model for EPEC infection closer to the in vivo conditions. A good established model to study EPEC infection is the infection of in vitro cultured human intestinal 
biopsies (IVOC), which allows the formation of A/E lesions undistinguishable from those observed in vivo in biopsies of patients with diarrhea by EPEC 
(Knutton, Lloyd et al. 1987, Hill, Phillips et al. 1991). Interestingly, it has 
been reported that EPEC strains deficient of phosphorylation of Tir Y474 
and Y454 are able to induce the A/E lesion formation in the IVOC infection in 
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an NcK-independent manner while the phosphorylation at these positions is crucial to induce the pedestal formation during in vitro infections of 
cultured cells lines (Schuller, Chong et al. 2007). In our work the infection of human duodenal biopsies by the effector mutant EPEC strains revealed 
that, although EPEC2 and EPEC1 strains were able to induce actin-pedestals 
in vitro, none of the infected biopsies with these strains showed A/E lesion, see Table 8 and Figure 30. Thus, Tir is not sufficient to induce A/E lesion and other effector besides Tir and EspZ are needed to induce the A/E lesion in 
intestinal surfaces. We further used the IVOC assay to characterize whether 
LEE or non-LEE effector(s) were involved to induce the A/E lesion. Infection 
of human biopsies with EPEC2-LEE+ (carrying all LEE effectors) did not 
reveal A/E lesions whereas infection with EPEC9 (espZ, tir and all the non-
LEE effectors) induced A/E lesions in biopsies with efficiency as high as the wild-type EPEC strain, see Table 8 and Figure 30. Therefore, non-LEE effectors are essential to induce A/E lesion in human intestinal tissue. It was 
previously reported that LEE confers the attaching and effacing phenotype to E. coli K-12 strains and it was observed by the A/E lesion formation 
in Caco-2 cells in vitro (McDaniel and Kaper 1997). Contrary, our results indicate that additional effectors are required for the A/E lesion formation and further reveal the importance of the IVOC assay to analyze effectors roles during infection. 
Most of the non-LEE effectors are implicated in counteracting the host 
immune response like NleB, NleE, NleC, NleD, NleH1, LifA and NleF. Although 
in vivo infection is the ideal situation to study the complete immune response against an infection, some studies have used intestinal biopsies tissues to analyze some immune response traits. It has been reported with an organ culture system using human intestinal biopsies that after stimulation, there 
is epithelial infiltration and lamina propia T-cell activation (Auricchio, 
Paparo et al. 2004).  Another studies evaluated the innate immune response of cultured human duodenal biopsies using a polarized IVOC system for optimal of bacterial-host cell interaction. Using this system they showed that 
apical EPEC infection of duodenal mucosa results in increased IL-8 mRNA 
and protein expression and that it was mainly dependent of flagellin and 
Toll like receptor 5 interaction (Schuller, Lucas et al. 2009). Therefore, we 
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speculated that non-LEE effectors could be necessary to block the immune response of the intestinal biopsies to enable the A/E lesion formation during 
ex vivo EPEC infection. 
With the aim of characterizing non-LEE effectors involved in A/E lesion, 
we infected human biopsies with EPEC8, EPEC7 and EPEC6; these strains 
have sequential deletion of effectors genes present in IE5, IE6 and IE2, respectively (Table 9). While IVOC infection with EPEC8 show efficient A/E 
lesion formation, infections with EPEC7 and EPEC6 reduced the efficiency 
of A/E lesion to 54% and 23% of the infected samples, respectively. The low 
efficiency induced with EPEC6 tempted us to analyze the contribution of IE6 
and IE2 encoded effectors. These two IEs encode a similar set of effectors, 
IE6 (espL, nleB1, nleE1 and efa1/lifA) and IE2 (espL*, nleB*, nleE2 and efa/
lifA-like) (Figure 31A). The espL* and nleB* effectors of IE2 are pseudogenes, which suggests that are nleE and/or efa1/lifA homologs the effectors 
playing a major role in A/E lesion formation. NleE2 has an internal deletion 
of 56 residues that could impede T3-translocation into HeLa cells (Nadler, 
Baruch et al. 2010).  Efa1/LifA-like has been reported to be T3-secreted by a hypersecreting EPEC mutant strain although there is no evidence of its 
translocation into HeLa cells (Iguchi, Thomson et al. 2009, Deng, Yu et al. 
2012). To investigate whether NleE2 or Efa1/LifA-like were responsible 
of the reduction in the A/E lesion formation by EPEC6, we generated the 
mutant strains EPEC7∆nleE2 and EPEC7∆lifA-like (Figure 31A). Since 
EPEC7∆lifA-like, and not by EPEC7∆nleE2, reduced the efficiency of A/E 
lesion formation of EPEC7, we propose that lifA-like is a non-LEE effector 
that has a major contribution for efficient A/E lesion formation by EPEC 
(Table 9). 
The lifA-like was first described in the genome of EPEC O127:H6 strain 
E2348/69 as a homolog of lifA with 28% aa identity with Lymphostatin 
(LifA) (Iguchi, Thomson et al. 2009). The lifA was first described in EPEC 
O127:H6 as a chromosomally encoded protein with a predicted molecular 
mass of 365 kDa, it has been shown to be translocated into mammalian 
cells in a T3SS-dependent manner (Klapproth, Scaletsky et al. 2000, Deng, 
Yu et al. 2012). LifA homologs are found in the genome of A/E pathogens, 
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LifA in Citrobacter rodentium, Efa1 in non-O157 EHEC strains, and the less 
homologous ToxB encoded by a pO157 plasmid in EHEC O157:H7 strain 
(Klapproth, Scaletsky et al. 2000, Abu-Median, van Diemen et al. 2006). LifA 
and Efa1 are nearly the same protein with 99% of aa identity, therefore they are named efa1/lifA (Deng, Yu et al. 2012). 
The N-terminus of Lymphostatin bears significant homology to the 
N-terminal catalytic domain of large clostridial toxins (LCTs) that contains 
a glycosyltransferase domain (Busch, Hofmann et al. 1998, Klapproth, 
Scaletsky et al. 2000). LifA, Efa1 and ToxB hold three distinct motifs: a glycosyltransferase motif, a cysteine protease motif and an aminotransferase 
II motif (Klapproth, Sasaki et al. 2005, Babbin, Sasaki et al. 2009, Deacon, 
Dziva et al. 2010). Efa1/LifA homologs have been implicated in blocking lymphocyte proliferation and activation of immune response, as adhesins and colonization factors, and inducing intestinal barrier disruption by 
manipulation of cellular Rho GTPases (Klapproth, Scaletsky et al. 2000, 
Badea, Doughty et al. 2003, Klapproth, Sasaki et al. 2005, Babbin, Sasaki et 
al. 2009, Deacon, Dziva et al. 2010). Given the different proposed roles of 
LifA homologs in A/E pathogens, they have been considered multitalented 
virulence factors (Klapproth and Meyer 2009). Interestingly, Efa1/LifA-like 
protein has the three conserved motifs found in Efa1/LifA, despite being a 
smaller protein with 30% of aa identity (Deng, Yu et al. 2012). Although, 
the coding region for the first 50 aa of this protein fused to Bla was not 
translocated into HeLa cells, we speculate that it could be an alternative mechanism of translocation for this protein independent of its N-terminal region. Some proteins could be secreted in a T3-depedent manner to the environment of the infection and play a role in the pathogenesis once in 
contact with the epithelial cells (Deng, Yu et al. 2012). While in vivo infection 
with EHEC and Citrobacter rodentium in calves and mice respectively, 
confirmed the important role of Efa1/ LifA in intestinal colonization 
(Klapproth, Sasaki et al. 2005, Deacon, Dziva et al. 2010), in vivo studies to 
evaluate the role of LifA/Efa1 during EPEC infection have not been reported 
so far. For the best of our knowledge, this is the first study that implicates EPEC efa1/lifA homologs as the major non-LEE virulence factors assisting A/E lesion formation in human intestinal tissues ex vivo. Despite the major 
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role unveiled for Efa1/LifA homologs in A/E lesion formation, our study also 
shows that these proteins are not essential for this process, since EPEC6 
stills induces A/E lesion formation in ca. 23% of infected biopsies. This 
indicates that non-LEE effectors encoded in PPs also participate in assisting Tir and EspZ for A/E lesion formation.  Together these results demonstrate 
an essential role of non-LEE effectors in the induction of the A/E lesion in ex vivo infections of human intestinal tissues by EPEC.  Various non-
LEE effectors contribute for efficient A/E lesion formation in an additive 
manner, being Efa1/LifA homologs major contributors, but not essential for this process. 
Potential applications of the effector mutant EPEC strains
The effector mutant EPEC strains are a useful biological tool to study the role of effectors in EPEC pathogenesis. Using these mutant strains we can 
translocate an individual effector or defined combination of effectors using 
in vitro infections of conventional nonpolarized culture cell lines, polarized 
cell lines of intestinal origin (e.g., Caco-2 and T84 cells), and human intestinal biopsies. EPEC is human enteric pathogen with a narrow host range, but some in vivo animal models are available for research. The larvae of Galleria 
mellonella, which possess like mammals a complex innate immune system, could be an interesting and simple model to evaluate the virulence of our effector mutant EPEC strains. It has been reported that bacterial strains attenuated in mammalian models demonstrate lower virulence in Galleria 
(Ramarao, Nielsen-Leroux et al. 2012). Also, it has been reported that EPEC strains defectives in T3SS lose their lethal effect in Galleria (Leuko and Raivio 
2012). Infection of mammalian models is important to evaluate the effect of innate and adaptive immune host-answer as well as components of the microbiota, which all together have protective role against A/E pathogens 
infection (Law, Gur-Arie et al. 2013). The oral infection with EPEC of neonate mice has been reported to induce an effective intestinal colonization associated with the generation of A/E lesion-like focal microcolonies in the intestinal epithelial surface, as well as mucosal innate immune stimulation, 
which were dependent on the presence of EPEC virulence factors (i.e., 
BFP and T3SS) (Dupont, Sommer et al. 2016). Therefore, oral infection of 
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newborn mice will be a relevant approach to evaluate in vivo the effector 
mutant strains and strains with defined effectors. 
Most effector mutant EPEC strains are likely to be strongly attenuated, whereas they maintain intact the external antigenicity of the wild-type strain. A mutant strain with a functional T3SS and the minimum set of effectors necessary to colonize and attach to the intestine surface, can be used to induce protection against EPEC but not the acute diarrhea that characterize EPEC infection.  Safe EPEC mutant strains with ability to colonize and attach to the human intestine can compete with the commensal microbiota for intestinal nutrient and niches and we can engineer them to translocate heterologous bacterial protein to generate immunity against 
other enteric pathogen such as: Vibrio cholera and Shigella spp.  Studies illustrate that bacterial outer membrane proteins are ideal molecules 
as vaccine antigens. The outer membrane protein A (OmpA) of Shigella 
flexneri 2a induces humoral and cellular immune response against Shigella 
spp. in mice (Pore and Chakrabarti 2013, Pore and Chakrabarti 2016).  The 
B subunit of cholera toxin (CTB) is a potent immunogen associated with protection against V. cholera (Price, McFann et al. 2013). The advantage of 
using CTB is that stimulation of the antitoxic immunity is complete safety, 
without the risk of the reversion of the toxoid (chemically-inactivated-
toxin) (Levine, Kaper et al. 1983). Thus, a vaccine based in killed whole cells of V. cholera plus recombinant cholera toxin B subunit has been used for human immunization against V. cholera (Organization 2010). Regarding 
EHEC enteric pathogens, immunogenic protection induced by selected 
protein(s) of EHEC has been reported, such as: Efa1, Intimin, EspB and the 
B subunit of the Shiga toxin 2 (Stx2)(Marcato, Griener et al. 2005, Szu and 
Ahmed 2014, Riquelme-Neira, Rivera et al. 2015, Rabinovitz, Larzabal et al. 
2016). Thus, genome engineering to drive expression these immunogenic proteins by the effector mutant EPEC strains will be a good approach for vaccine development to these and other enteric pathogen.  
The effector mutant strains can also be potential therapeutic tools for the 
treatment of intestinal inflammatory and autoimmune disorders. Patients 
with inflammatory bowel diseases (IBDs), including Crohn´s disease (CD) 
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and ulcerative colitis (UC), are characterized by abnormal activation of the 
immune system in the gut, resulting in chronic inflammation of the digestive 
system (Martin, Miquel et al. 2013). Recombinant lactic acid bacteria (LAB) have been engineered to express immunomodulatory molecules for the 
treatment of IBDs. Secretion of the anti-inflammatory cytokine IL-10 by the recombinant Lactococcus lactis induced beneficial effect in mouse models of 
IBD (Steidler, Hans et al. 2000). A phase II clinical trial with L. lactis expressing 
IL-10 revealed that although safety, tolerability and environmental 
containment have been achieved, no statistically significant difference has 
been found versus placebo in beneficial effects (Martin, Miquel et al. 2013). Due to this outcome, a good approach will be optimization of the delivery system. Therefore, a good possibility will be to use recombinant effector 
mutant EPEC strains having good colonization to translocate the IL-10 
cytokine into the enterocytes of patients with IBDs. This can be extended to 
the translocation of defined effectors downregulating the immune response 
(e.g. acting on NF-kB signalling). In summary, we anticipate interesting applications of the effector mutant EPEC strains generated in this PhD thesis in basic research, vaccine development, and therapeutic interventions against autoimmune disorders in the gastrointestinal tract.
123
CONCLUSIONS
124
CONCLUSIONS125
1. We have deleted the whole repertoire of T3SS effectors found in the ge-nome of EPEC serotype O127:H6 strain E2348/69 through a markerless gene deletion strategy. Deletions were done from the start codon to the stop codon of individual ORFs or cluster of effectors, maintaining the assembly of a functional T3SS injectisome and without affecting growth, viability and cellular morphology of the bacteria. 
2. All the effector mutant strains carrying Tir are able to trigger actin polym-erization in pedestal-like structures underneath bacteria attached to HeLa cells. All effector mutant strains and the effector-less strain (EPEC0) trans-locate substrates of the T3SS (i.e., EspF1-20-Bla) into HeLa cells. 
3. Deletion of the myosin interacting domain (mid) of EspB translocator protein does not disrupt T3SS-protein translocation but dramatically re-duces translocation levels. 
4. The strain harboring Tir and lacking EspZ (EPEC1) translocates higher levels of T3SS substrates and induces higher cytotoxicity in HeLa cells. The absence of EspZ in EPEC1 leads to a higher level of Tir translocation into HeLa cells than that of EPECwt. The translocation of Tir by EPEC2, express-ing Tir and EspZ, is lower than that of EPECwt, suggesting that additional effector(s) may be necessary to stabilize Tir in HeLa cells.  
5. Following a markerless gene integration strategy, a single copy of gene-encoding effectors espH, map, and nleC were integrated in their native loci within LEE and PP4 of effector mutant strains EPEC2, EPEC1 and EPEC0. The individual translocation of EspH, Map and NleC from single chromo-somal gene copy and native gene expression induced the reported pheno-
types of focal adhesion disassembly (EspH), filopodia formation (Map) and p65 degradation (NleC). Therefore, the effector mutant strains are useful to study the phenotype caused by individual effectors in the context of EPEC infection and physiological expression levels of the effectors. 
6. Strains expressing Tir (EPEC1) or Tir and EspZ (EPEC2) effectors alone were not able to induce A/E lesions in human intestinal biopsies, despite 
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inducing actin pedestal-like structures in HeLa cells. Hence, Tir effector is 
required but not sufficient to induce A/E lesions in ex vivo infections of hu-man intestinal tissues.  
7. EPEC requires the expression of a subset of non-LEE effectors to induce A/E lesion in human intestinal biopsies. The EPEC effector mutant strain maintaining all six LEE effectors and devoid of all non-LEE effectors (EPEC2-LEE+) was unable to induce A/E lesions in human intestinal biopsies. 
8. Non-LEE effectors encoded in IE6, IE2 and PPs have an additive role in 
augmenting the efficiency of A/E lesion formation in human intestinal bi-opsies. Deletion of IE6 and IE2 encoded effectors (EPEC6) dramatically re-
duces the efficiency of the A/E lesion formation from wild-type levels (ca. 76%) to ca. 54% in EPEC7 (∆IE6) and ca. 23% in EPEC6 (∆IE6∆IE2). The Efa1/LifA homologs encoded in IE6 and IE2 are the major contributors for 
the development of efficient A/E lesions in human intestinal tissues. In the absence of Efa/LifA homologs, the effectors encoded in PPs, together with 
Tir and EspZ, still allow A/E lesion formation by EPEC at low efficiencies (ca. 23-33%). 
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1. Hemos delecionado todo el repertorio de efectores del T3SS en el genoma del EPEC serotipo O127:H6 cepa E2348/69 a través de una estrategia de deleción libre de marcas. Las deleciones fueron hechas desde el codón de inicio hasta el codón 
de finalización de las ORFs individuales o grupos de efectores, manteniendo el co-
rrecto ensamblado de los inyectisomas del T3SS y sin afectar al crecimiento, la viabilidad o la morfología de las bacterias.
2. Todas las cepas mutantes en efectores que llevaban Tir son capaces de desen-
cadenar la polimerización de actina en estructuras en forma de pedestal bajo las bacterias unidas a células HeLa.  Todas las cepas mutantes en efectores y la cepa 
sin efectores (EPEC0) translocan sustratos del T3SS (ej. EspF1-20-Bla) al citoplasma de células HeLa.
3. La deleción del dominio de interacción con miosina (mid) de la proteína trans-locadora EspB no impide la translocación de proteínas por el T3SS pero reduce drásticamente los niveles de translocación. 
4. La cepa que presenta Tir y carece de EspZ (EPEC1) transloca mayores niveles de substratos del T3SS e induce mayor citotoxicidad en células HeLa. La ausencia de EspZ en EPEC1 conlleva  niveles de translocación de Tir a células HeLa mayores 
que los producidos por la cepa EPECwt. La translocación de Tir en la cepa EPEC2, 
que expresa Tir y EspZ, es menor que la del EPECwt, lo que sugiere que otros efec-
tores podrían necesitarse  para estabilizar Tir en células HeLa.
5. Siguiendo una estrategia de integración libre de marcas, una copia única de los 
genes codificantes de los efectores espH, map and nleC fueron integrados en su sitio 
original en el LEE y en el PP4 de las cepas mutantes en efectores EPEC2, EPEC1 y 
EPEC0. La translocación individual de EspH, Map y NleC desde una copia única en 
el cromosoma y bajo regulación nativa indujo los fenotipos previamente reporta-
dos de desensamblado de las adhesiones focales (EspH), formación de filopodios 
(Map) y degradación de p65 (NleC). Por lo tanto, las cepas mutantes en efectores 
son útiles para estudiar el fenotipo causado por efectores individuales en el con-
texto de la infección de EPEC con niveles de expresión fisiológicos de los efectores.
6. Las cepas expresando únicamente los efectores Tir (EPEC1) y Tir y EspZ (EPEC2) 
no fueron capaces de inducir lesiones A/E en biopsias intestinales humanas, a pe-sar de inducir la formación de estructuras en forma de pedestales de actina en 
células HeLa. Así, Tir es necesario pero no suficiente para inducir la formación de la lesión A/E durante la infección ex vivo de tejidos humanos intestinales.
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7.  EPEC necesita la expresión de un subconjunto de efectores no-LEE para inducir la lesión A/E en biopsias intestinales humanas. La cepa mutante en efectores que mantiene los seis efectores del LEE y está desprovista de todos los efectores no-LEE (EPEC2-LEE+) fue incapaz de inducir la formación de la lesión A/E en biopsias intestinales humanas. 
8. Los efectores no-LEE codificados en IE6, IE2 y PPs presentan un papel aditivo 
para aumentar la eficiencia en la formación de la lesión A/E en las biopsias intesti-
nales humanas. La deleción de los efectores codificados en IE6 y IE2 (EPEC6) redu-
jo dramáticamente la eficiencia de la formación de la lesión A/E,  desde niveles de 
la cepa EPECwt (aprox. 76%) a aprox. 54% en el EPEC7 (∆IE6) y aprox. 23% en el 
EPEC6 (∆IE6∆IE2). Las proteínas homologas a Efa1/LifA codificadas en IE6 y IE2 
son las que contribuyen principalmente al desarrollo eficiente de la lesión A/E en 
tejidos humanos intestinales.  En ausencia de las proteínas homologas Efa1/LifA, 
los efectores codificados en los PPs, junto a Tir y EspZ, aún permiten la formación 
de la lesión A/E por EPEC pero con una baja eficiencia (aprox. 23-33%).
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